9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. Advancing the impact of angiogenesis inhibitors: views from a basic scientist 9th International Congress on the Future of Breast Cancer, La Jolla California July, 2010
2. Heterogeneous impact of antiangiogenic drugs and/or metronomic chemotherapy on micro- vs macroscopic metastatic disease Tianjin International Conference on Tumor Microenvironment July, 2010
3. Preclinical strategies for improving clinical outcomes of antiangiogenic drug-based therapies Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai China July, 2010
4. A rationale for undertaking particular clinical biomarker studies of sunitinib therapy based on prior preclinical findings Sunnybrook Health Sciences Centre 5th Annual Cancer Research Day, Toronto June, 2010
5. Contrasting effects of VEGF pathway targeting antibodies and TKIs on microscopic versus advanced metastatic disease Keynote Lectureship Series, Center for Integrative Biology and BioTherapeutics (CIBB), Pfizer Biopharmaceuticals, Pearl River June, 2010
6. Contrasting effects of VEGF pathway targeting antibodies and TKIs on microscopic versus advanced metastatic disease American Society for Clinical Oncology (ASCO) 2010 annual meeting, Chicago June, 2010
7. Targeted (and non-targeted) vascular therapy of the tumor microenvironment German Cancer Research Center DKFZ Symspoium on Targeted Cancer Therapy May, 2010
8. Debate on angiogenesis: is antiangiogenic therapy dead in breast cancer? Biologist Introduction IMPAKT 2010 Breast Cancer Conference May, 2010
9. Truth & consequences: antiangiogenic therapies in cancer Clinical Care Options (CCO) CME Program on Antiangiogenic Therapies in Cancer (Virtual Presentation) May, 2010
10. A translational research strategy for designing more effective treatments for advanced ovarian cancer 5th Canadian Conference on Ovarian Cancer Research, Toronto May, 2010
11. Rationale underlying preclinical CYT997 'metronomic' efficacy program in the Kerbel lab YM Biosciences Key Opinion Leader Meeting April, 2010
12. Forum on Antiangiogenic therapy-induced malignant progression: preclinical anomaly or clinical reality? Moderator, 101st AACR annual meeting, Washington April, 2010
13. Undesirable) therapy-induced alterations of the tumor microenvironment by BMDCs and how to prevent them 101st AACR Annual Meeting 2010 - Tumor Microenvironment Working Group Town Meeting, Washington April, 2010
14. Contrasting impact of antiangiogenic drugs (antibodies versus TKIs) and metronomic chemotherapy on early stage or advanced metastatic cancers Northwestern University, Chicago March, 2010
15. Will antiangiogenic drugs be more effective for metastatic disease than as neoadjuvant or adjuvant therapies? Acceleron Pharma, Inc., Boston March, 2010
16. Contrasting impact of antiangiogenic drugs (antibodies versus TKIs) and metronomic chemotherapy on early stage or advanced metastatic cancers Vascular Biology Seminar, Childrens Hospital, Boston March, 2010
17. Contrasting impact of antiangiogenic drugs (antibodies versus TKIs) and metronomic chemotherapy on early stage or advanced metastatic cancers ArQule, Boston March, 2010
18. Contrasting impact of antiangiogenic drugs (antibodies vs TKIs) in early stage or advanced metastatic cancers Roswell Park Cancer Institute, Buffalo March, 2010
19. Contrasting impact of antiangiogenic drugs (antibodies versus TKIs) and metronomic chemotherapy on early stage or advanced metastatic cancers Sunnybrook Health Sciences Centre, Molecular & Cellular Biology Research Journal Club March, 2010
20. Combination metronomic chemotherapy and antiangiogenic drug treatments: recent preclinical and clinical advances Kitasato University School of Medicine, Tokyo Japan February, 2010
21. Will antiangiogenic drugs be more effective for metastatic disease than as neoadjuvant or adjuvant therapies? the 12th International Symposium on Anti-angiogenic Agents: Recent Advances and Future Directions in Basic and Clinical Cancer Research February, 2010
22. Metronomic chemotherapy: recent preclinical and clinical advances The 6th OOTR Annual Conference: Oncological Biomarker and Clinical Applications, Kyoto Japan February, 2010
23. Antiangiogenic drugs and metronomic chemotherapy for breast cancer treatment (SDF-1) The Expedition Inspiration Fund for Breast Cancer Research 14th Annual Laura Evans Memorial Breast Cancer Symposium New Targets for Breast Cancer Therapy, Sun Valley Idaho February, 2010
24. Contrasting effects of different antiangiogenic drugs (TKIs and antibodies) on early vs late stage metastatic disease AACR-IASLC Joint Conference: Lung Cancer, San Diego January, 2010
25. Overview of metronomic (chemo)therapy YM Biosciences, Mississauga Ontario January, 2010
26. Overview of vascular disrupting agents YM Biosciences, Mississauga Ontario January, 2010
27. Mechanisms and consequences of antiangiogenic therapy and tumor vascular disrupting agents in early and advanced stage cancer FACT Investigator Meeting, Budapest November, 2009
28. New preclinical model to study the biology and treatment of spontaneous melanoma brain metastases Society for Melanoma Research 2009 International Congress, Boston November, 2009
29. Mechanisms and therapeutic targets associated with the tumor microenvironment and angiogenesis Keynote Lecture, the 7th Asia Pacific Oncology Summit, Taipei, Taiwan October, 2009
30. Translational research studies of antiangiogenic therapy in the advanced metastatic and adjuvant breast cancer settings AACR Special Conference - Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Diego October, 2009
31. Preclinical translational studies for improving the success of anti-cancer therapies for metastatic disease in the clinic Keynote Lecture, 1st Annual Meeting of the Center for Translational Molecular Medicine (CTMM), Utrecht October, 2009
32. Taking low-dose metronomic chemotherapy from a preclinical concept to a promising clinical treatment for metastatic disease 24th Annaul Offering of Critical Issues inTumor Microcirculation, Angiogenesis and Metastasis - Biological Significance and Clinical Relevance, Harvard Medical School, Dept. of Continuing Education and Massachusetts General Hospital (Dept. of Radiation Oncology), Boston September, 2009
33. Mechanisms and consequences of antiangiogenic therapy of early and advanced stage cancer Plenary Lecture, 80th Annual Meeting of the American Thyroid Association, Palm Beach September, 2009
34. Some issues of current interest regarding EGFR, tumor angiogenesis, and antiangiogenics Bristol Myers Squibb EGFR/Biomarker Summit 2009, Philadelphia September, 2009
35. A paradox in the making: will antiangiogenic drugs be more effective for metastatic disease than as neo-adjuvant or adjuvant therapies? Gordon Research Conference on Angiogenesis, Newport August, 2009
36. Status of antiangiogenic drugs for the treatment of cancer 2009 Semester 2 Amgen Canada Meeting, Toronto July, 2009
37. Recent advances in the development and application of antiangiogenic therapy for cancer 2009 ACVIM Forum & Canadian Veterinary Medical Association Convention, Montreal June, 2009
38. Strategies for improving antiangiogenic-based treatments for the adjuvant and metastatic therapy of breast cancer Institute of Cancer Research, Breakthrough Breast Cancer Research Centre, London June, 2009
39. Translational research studies of antiangiogenic therapy for advanced metastatic disease Keynote Lecture, Montreal International Symposium on Angiogenesis and Metastasis, Montreal June, 2009
40. Some unexpected outcomes of therapeutically interfering with VEGF pathway function Annual Pezcoller Symposium June, 2009
41. Translational approaches to improving metronomic low-dose chemotherapy for treatment of advanced metastatic disease 2009 ACVIM Forum & Canadian Veterinary Medical Association Convention June, 2009
42. Discussion of abstract #5502, "Combretastatin A4 phosphate (CA4P, fosbretabulin) carboplatin and paclitaxel in patients with platinum resistant ovarian cancer: final phase II trial results by Zweifel et al., ASCO 2009 Annual Meeting, Clinical Science Symposium: New Advances in Gynecologic Cancers June, 2009
43. Antiangiogenic drugs including Avastin for the treatment of cancer: whats new and where do we go from here Roche Canada, Mississauga May, 2009
44. Mechanisms and consequences (both good and bad) of antiangiogenic therapy for metastatic disease University of Maryland, Marlene & Stewart Greenbaum Cancer Center “Frontiers in Oncology Grand Rounds, Baltimore May, 2009
45. Issues regarding the impact of antiangiogenic drugs and metronomic chemotherapy for metastatic breast cancer 14th Taiwan Joint Cancer Conference, Taipei May, 2009
46. Mechanisms and consequences of therapeutically inhibiting tumor angiogenesis The New York Academy of Sciences, Biochemical Pharmacology Discussion Group Symposium “Expanding Role of Angiogenesis in Cancer Therapeutics: The Folkman Legacy May, 2009
47. Preclinical strategies for improving the impact of antiangiogenic therapies in patients with metastatic disease 2009 Gairdner Foundation International Cancer Symposium, Edmonton May, 2009
48. Antiangiogenic targeted therapy and metronomic chemotherapy: preclinical and clinical advances Kurume University, Kurume April, 2009
49. Mechanisms and consequences of vascular targeting therapy using antiangiogenic drugs or vascular disrupting agents Oxigene, Inc., San Francisco April, 2009
50. Mechanisms of resistance to targeted antiangiogenic drugs and the impact of metronomic chemotherapy combined with an antiangiogenic drug Cancer Institute Hospital of Japanese Foundation for Cancer Research April, 2009
51. Metronomic chemotherapy for metastatic cancer: preclinical and clinical advances Kyushu University, Fukuoka, Japan April, 2009
52. Metronomic UFT-based chemotherapy for cancer treatment Luncheon Seminar for the Japan Society of Obstetrics & Gynecology April, 2009
53. Advances in the application of metronomic chemotherapy for the treatment of breast cancer or ovarian cancer Meet the Expert lecture, Session 2: Oncology for the 61st Annual Congress of Japan Society of Obstetrics & Gynecology (JSOG April, 2009
54. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer 11th International Conference on Primary Therapy of Early Breast Cancer – Evidence, Controversies, Consensus March, 2009
55. Some mechanisms and consequences of antiangiogenic targeting of the VEGF pathway in cancer 15th Scientific Symposium of the Lilly Foundation – Molecular Markers in Cancer Therapy: Present Use and Future Perspectives, Madrid March, 2009
56. Antiangiogenic drugs for the treatment of cancre: past, present, and the near future Department of Medicine Medical Grand Rounds, Sunnybrook Health Sciences Centre, Toronto February, 2009
57. Mechanisms and consequences of therapeutically inhibiting tumor angiogenesis Distinguished Lecture, Sylvester Comprehensive Cancer Center, Leonard M. Miller School of Medicine, Miami February, 2009
58. Implications of altered malignant aggressiveness induced by antiangiogenic drug therapy 11th International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Basic and Clinical Cancer Research February, 2009
59. Rapid systemic induction of proangiogenic/vasculogenic factors by chemotherapy or antiangiogenic drugs: implications for tumor progression and response to therapy Keystone Symposium: Angiogenesis and Lymphangiogenesis in Cancer, Big Sky, Montana January, 2009
60. Past, present, and future of antiangiogenesis therapy Molecular Oncology: The 6th Vital Sign, What Every Oncologist Should Know January, 2009
61. Translational studies of antiangiogenic drug enhancement of standard or metronomic chemotherapy for treating advanced metastatic disease Keynote Lecture, 3rd European Conference on Tumor Angiogenesis and Antiangiogenic Therapy, Padova Italy November, 2008
62. Antiangiogenic therapy: some factors to consider for combination treatment strategies and confronting drug resistance Acceleron Pharma, Inc., Boston November, 2008
63. Translational research strategies for improving antiangiogenic drug – metronomic chemotherapy of advanced metastatic cancer University of Guelph Distinguished Seminar Series, Guelph Ontario October, 2008
64. Strategies for more effective clinical translation of metronomic low-dose (antiangiogenic) chemotherapy in the treatment of metastatic breast cancer JBCS-IABCR Joint Symposium, Osaka Japan October, 2008
65. Translational research strategies for improving antiangiogenic drug – metronomic chemotherapy of advanced metastatic cancer University of California, San Francisco Friday Seminar Series, San Francisco October, 2008
66. Resistance to VEGF-targeting agents 7th International Symposium on Translational Research in Oncology, Huntington Beach October, 2008
67. Considerations for integrating antiangiogenic drugs with vascular disrupting agents or chemotherapy Onyx Pharmaceuticals, San Francisco October, 2008
68. Rapid clinical translation of metronomic chemotherapy for the treatment of metastatic breast cancer 26th Congress of the International Association for Breast Cancer Research (IABCR), Kurashiki Japan September, 2008
69. Antiangiogenesis and metronomic chemotherapy: current status and future perspectives Symposium of Cancer Research for Angiogenesis and Therapy, Tainan Taiwan September, 2008
70. Antiangiogenesis and metronomic chemotherapy: current status and future perspectives The Chinese Oncology Society, Taipei Taiwan September, 2008
71. Strategies for improving antiangiogenic drug-based therapies for advanced metastatic disease Michigan Clinical Research Symposium, Inaugural Symposium 2008, Clinical Research to Clinical Practice: Managing Challenges at the Cutting Edge September, 2008
72. VEGF pathway targeting antiangiogenic drugs: what exactly is the target? 2008 Breast Cancer Symposium, Washington September, 2008
73. Mechanisms and consequences of antiangiogenic drug therapy for the treatment of advanced metastatic disease Enzon Pharmaceuticals, Inc., New Jersey September, 2008
74. Metronomic therapy and the organ microenvironment Molecular Therapeutics of Cancer Research Conference August, 2008
75. Acceleration of metastasis by short-term sunitinib monotherapy AVEO Pharmaceuticals, Inc., Boston July, 2008
76. Metronomic low dose antiangiogenic chemotherapy in mice and men The IXth World Conference on Clinical Pharmacology and Therapeutics, Quebec City July, 2008
77. Bedside-to-bench aspects of breast cancer angiogenesis and antiangiogenic therapy 3rd Annual Biological Basis of Breast Cancer Conference: The Science & Art of Clinical Care July, 2008
78. Proposed mechanisms responsible for increased chemotherapy efficacy induced by (VEGF-pathway targeting) antiangiogenic drugs AVEO Pharmaceuticals, Inc., Boston July, 2008
79. Taking low-dose metronomic chemotherapy from a preclinical concept to a promising clinical treatment for advanced metastatic disease 23rd Annaul Offering of Critical Issues inTumor Microcirculation, Angiogenesis and Metastasis - Biological Significance and Clinical Relevance, Harvard Medical School, Dept. of Continuing Education and Massachusetts General Hospital (Dept. of Radiation Oncology), Boston June, 2008
80. Antiangiogenic and metronomic chemotherapy: an approach to reducing the disparity between preclinical and clinical results 10th Milan Breast Cancer Conference June, 2008
81. Special Lecture to the memory of Judah Folkman 10th Milan Breast Cancer Conference, Milan June, 2008
82. Amplifying the efficacy of metronomic or standard chemotherapy (or VDAs) using targeted antiangiogenic drugs San Raffaele Scientific Institute, Milan June, 2008
83. Amplifying standard or metronomic chemotherapy efficacy using antiangiogenic VEGF pathway targeting drugs National Cancer Institute, Mouse Cancer Genetics Program, Frederick June, 2008
84. Discussion of Presentations by R. Pili & J. Lickliter ASCO 2008 Annual Meeting, Clinical Science Symposium - Novel Antiangiogenic Mechanisms. June, 2008
85. Antiangiogenic drugs on defense: impact of bone marrow endothelial progenitor cells on tumor response to chemotherapy and vascular disrupting agents Mario Negri Institute for Pharmacological Research June, 2008
86. Implications of the rapid and systemic induction of multiple proangiogenic mediators by chemotherapy or antiangiogenic drugs Keynote lecture, University at Buffalo, The State University of New York Pharmacology Day May, 2008
87. Antiangiogenic drugs on defense: impact of endothelial progenitor cells on tumor response to chemotherapy and vascular disrupting agents Ottawa Health Research Institute Invited Seminar May, 2008
88. Preclinical strategies for improving antiangiogenic drug-based therapies for advanced metastatic disease 7th Annual Anne and Max Tanenbaum Chair Symposium in Biomedical Research, Toronto May, 2008
89. Amplifying standard or metronomic chemotherapy efficacy using antiangiogenic VEGF pathway targeting drugs Keynote lecture, Ontario Cancer Institute Applied Molecular Oncology Division Retreat May, 2008
90. Issues in the Modulation of Angiogenesis Pathways ASCO 2008 Annual Meeting, Meet the Professor Session May, 2008
91. Tribute to Dr. Judah Folkman AACR annual meeting April, 2008
92. A therapeutic revolution; targeting new pathways the role of VEGFR and PDGFR in cell proliferation, migration, and survival Pfizer-sponsored Science Writers Workshop April, 2008
93. Successful clinical translation of antiangiogenic drug metronomic chemotherapy for advanced metastatic cancer University at Buffalo, The State University of New York, Department of Pharmaceutical Sciences Invited Seminar April, 2008
94. Targeting cancer's lifelines: a new approach to treatment Ontario Institute for Cancer Research Public Lecture April, 2008
95. Evaluation of (two) proposed mechanisms to explain the chemosensitizing ability of antiangiogenic drugs - and how they impact on different outcomes using MAbs vs RTKIs GlaxoSmithKline Pazopanib Chemotherapy Advisory Board Meeting April, 2008
96. Amplifying standard or metronomic chemotherapy efficacy using antiangiogenic VEGF pathway targeting drugs AACR annual meeting, symposium on “Novel Mechanisms of Tumor Angiogenesis, San Diego April, 2008
97. Translating low-dose metronomic chemotherapy into the clinic for the treatment of advanced metastatic breast cancer Novel Targeted Cancer Therapies: from Cell and Mice to Patients", Nobel Forum, Karolinska Institute, Stockholm March, 2008
98. Preclinical strategies for effective clinical translation of antiangiogenic drug - metronomic chemotherapy for metastatic breast cancer Weizmann Institute, Michael Feldman Memorial Lecture, Tel Aviv March, 2008
99. Translating metronomic antiangiogenic chemotherapy into the clinic for advanced metastatic cancer AACR International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, Jordan, March, 2008
100. Changes in circulating ligand after treatment with RTKI targeting drugs: why they may not be informative but how they might/could be Bristol-Myers Squibb EGFR Summit, Orlando February, 2008
101. Assessment of anti-angiogenic drug/metronomic chemotherapy regimens in models of advanced metastatic disease: some surprising findings The 9th International Symposium on Anti-Angiogenic Agents (ISAAA) – Recent Advances and Future Direction in Basic and Clinical Cancer Research, La Jolla California February, 2008
102. Preclinical studies of (some) potentially promising biomarkers for antiangiogenic drugs National Cancer Institute of Canada Clinical Trials Group Biomarkers and Angiogenesis Inhibitor Meeting, Toronto February, 2008
103. Molecular targeted therapies for cancer treatment: targeting tumor angiogenesis, oncogene signalling, DNA repair (and the endothelin receptor) as examples AstraZeneca Preceptorship Workshop February, 2008
104. Overview: therapeutic implications of VDA (and chemotherapy)-induced spikes in circulating endothelial progenitor cells Oxigene, Inc., Boston January, 2008
105. An approach for the development of models to study spontaneous CNS metastases National Cancer Institute – Biology of Brain Metastasis Meeting January, 2008
106. Combining VEGF pathway targeting drugs with metronomic chemotherapy: rationale and preclinical/clinical updates ImClone Systems, New York December, 2007
107. Impact of bone marrow derived circulating endothelial progenitor cells on response to vascular targeting therapies, and conventional or metronomic chemotherapy Distinguished Lecture, UT Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center Cancer Grand Rounds, Dallas November, 2007
108. Metronomic chemotherapy with a targeted antiangiogenic drug for treatment of advanced metastatic disease Plenary Lecture, The 4th Annual Conference of the Organization for Oncology and Translational Research, Kyoto Japan November, 2007
109. How a targeted antiangiogenic drug may amplify the efficacy of conventional chemotherapy The Joint Meeting of the 4th ISC International Conference on Cancer Therapeutics and The 7th Princess Margaret Hospital Conference: New Developments in Cancer Management November, 2007
110. Impact of bone marrow derived circulating endothelial progenitor cells on response to vascular targeting therapies and conventional or metronomic chemotherapy University of Michigan Comprehensive Cancer Center Cancer Center Research Fall Symposium, Ann Arbor November, 2007
111. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs Plenary Lecture, The 12th Annual Fall Symposium of Korean Cancer Association, November, 2007
112. Interaction of targeted antiangiogenic drugs with conventional or metronomic chemotherapy: preclinical & clinical update Seattle Genetics, Seattle October, 2007
113. Antiangiogenic therapy for cancer using targeted antiangiogenic drugs such as Avastin Roche Internal Training Seminar on Introduction to Oncology, Mississauga October, 2007
114. Interaction of targeted antiangiogenic drugs with conventional or metronomic chemotherapy: preclinical & clinical update Roswell Park Cancer Institute Medical Grand Rounds, Buffalo September, 2007
115. Antiangiogenic drugs on defense: impact of CEPs on tumor response to chemotherapy and VDAs Biogen Idec, Boston September, 2007
116. Antiangiogenic drugs on defense: impact of CEPs on tumor response to chemotherapy and VDAs Gordon Research Conference on Angiogenesis & Microcirculation, Newport, Rhode Island August, 2007
117. Tumor angiogenesis and antiangiogenic therapy: basic science update 2nd Annual Biological Basis of Breast Cancer Conference - The Science and Art of Clinical Care, Santa Monica July, 2007
118. The VEGF pathway as a therapeutic target in cancer The VEGF Education Resource Network (VERN) meeting, Newport Beach California June, 2007
119. Metronomic low dose antiangiogenic chemotherapy for adjuvant or metastatic cancer therapy Special Lecture, 43rd Annual Meeting of Liver Cancer Study Group of Japan (LCSGJ), Tokyo Japan June, 2007
120. Pharmacological modulation of the efficacy of chemotherapy by antiangiogenic drugs: impact of circulating endothelial progenitor cells 33rd Italian Society of Pharmacology meeting (Simposio su Angiogenesi Tumorale e Terapia Antiangiogenica June, 2007
121. Antiangiogenic metronomic chemotherapy: markers and mechanisms in mice and men 22nd Annaul Offering of Critical Issues inTumor Microcirculation, Angiogenesis and Metastasis - Biological Significance and Clinical Relevance, Harvard Medical School, Dept. of Continuing Education and Massachusetts General Hospital June, 2007
122. Introduction to circulating biomarkers (protein- and cell-based) for antiangiogenic therapy 1st Bevacizumab (Avastin) Antiangiogenesis Diagnostic Summit, Bethesda May, 2007
123. Bevacizumab enhancement of chemotherapy efficacy: how does it happen? 2nd Angiogenesis Course on Angiogenesis: A Key Target in Oncology, Barcelona Spain May, 2007
124. Cytotoxic therapy-induced bone marrow derived cell angiogenesis / vasculogenesis: implications for conventional or metronomic chemotherapy and vascular targeting therapy for cancer Genzyme Corporation, Boston May, 2007
125. Progress in metronomic antiangiogenic chemotherapy Meet-the-Expert Sunrise Session, 2007 AACR Annual Meeting, Los Angeles April, 2007
126. Rationale for a phase II trial of metronomic UFT and cyclophosphamide in MBC Toronto-Sunnybrook Regional Cancer Centre Breast Site Group Presentation, Toronto ON April, 2007
127. Mechanisms to explain the ability of antiangiogenic drugs such as bevacizumab to enhance the efficacy of chemotherapy Sudbury Regional Hospital Regional Cancer Program April, 2007
128. In vivo tumor models – gaps and possible solutions National Cancer Institute – Pathways to Patients Workshop March, 2007
129. Combinatorial metronomic antiangiogenic chemotherapy regimens for the treatment of advanced visceral metastatic cancer Forty Years of Metastasis Research: A Symposium in Honor of Dr. Isaiah J. Fidler, MD Anderson Cancer Center, Houston Texas March, 2007
130. Antiangiogenesis as anti-cancer targets The 3rd Strategic Directions in Cancer Therapy Symposium March, 2007
131. Molecular and cellular biomarkers for targeted antiangiogenic drugs and metronomic chemotherapy The 9th International Symposium on Anti-Angiogenic Agents (ISAAA) – Recent Advances and Future Direction in Basic and Clinical Cancer Research, La Jolla California February, 2007
132. Progress in the application of low dose metronomic antiangiogenic chemotherapy for the treatment of advanced metastatic disease Dyax Corporation, Boston January, 2007
133. VEGF as a therapeutic target for antiangiogenic therapy: preclinical and clinical update Invited seminar, Chugai Pharmaceutical Co., Ltd December, 2006
134. How is the efficacy of chemotherapy for cancer improved by using antiangiogenic drugs? Invited Seminar - Health Sector of the Biotechnology Research Institute & National Research Council of Canada, Montreal December, 2006
135. Progress in the application of low dose metronomic antiangiogenic chemotherapy for the treatment of advanced metastatic disease Keynote lecture, The Joint Meeting of 3rd ISC-International Conference on Cancer Therapy & 11th International Symposium on Cancer Chemotherapy, Tokyo Japan December, 2006
136. How is the efficacy of chemotherapy for cancer improved by using antiangiogenic drugs Invited Seminar - Health Sector of the Biotechnology Research Institute & National Research Council of Canada December, 2006
137. Anti-VEGF therapy for (colorectal) cancer Chugai Pharmaceuticals Co., Ltd. Investigators' Meeting for Colorectal Cancer, Tokyo Japan December, 2006
138. Progress in the application of low dose metronomic antiangiogenic chemotherapy for the treatment of advanced metastatic disease Keynote lecture, The Joint Meeting of 3rd ISC-International Conference on Cancer Therapy & 11th International Symposium on Cancer Chemotherapy December, 2006
139. Metronomic chemotherapy and approaches to maximizing the chemosensitizing properties of antiangiogenic drugs 18th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics, Prague November, 2006
140. Molecular Targets VEGF (Tumor Angiogenesis Seminar on Biology Targets for Cancer Therapy, Roche Canada, Mississauga November, 2006
141. Developments in the systemic treatment of renal cancer: rationale for antiangiogenic drugs targeting VEGF and PDGF function XVII Brazilian Cancer Congress, Round Table - Progress in the treatment of Renal Cancer, Belo Horizonte November, 2006
142. Scientific rationale underlying the use of multi-targeting antiangiogenic receptor tyrosine kinase inhibitor drugs Pfizer Satellite Symposium, Belo Horizonte, Brazil November, 2006
143. Metronomic chemotherapy and approaches to maximizing the chemosensitizing properties of antiangiogenic drugs Brazilian Congress of Cancerology Pre-Congress Course, Belo Horizonte, November, 2006
144. New developments in tumor angiogenesis and antiangiogenic therapy Juravinski Cancer Centre, Regional Oncology Rounds, Hamilton November, 2006
145. Approaches to maximizing the chemosensitizing properties of antiangiogenic drugs Milano New Drugs - Angiogenesis, Environment and Stroma: Models, Research and Care, Milan Italy November, 2006
146. Approaches to maximizing the chemosensitizing properties of antiangiogenic drugs Arlington Cancer Center CME Program, Arlington Texas November, 2006
147. Progress in the application of low dose metronomic antiangiogenic chemotherapy for the treatment of advanced metastatic disease 2nd Mayo Clinic Angiogenesis Symposium, Rochester Minnesota October, 2006
148. Progress in the application of low dose metronomic antiangiogenic chemotherapy for the treatment of advanced metastatic disease Taiho Pharmaceuticals, Inc. Antiangiogenesis Investigators meeting October, 2006
149. Antiangiogenic drugs for cancer treatment: update of an evolving and successful therapeutic strategy Pfizer Oncology Forum - From Pathways to Patients, Dublin Ireland October, 2006
150. How antiangiogenic drugs improve chemotherapy: is targeting circulating bone marrow derived endothelial progenitor cells the key? Princes Margaret Hospital, Medical Oncology Training Program October, 2006
151. How antiangiogenic drugs improve chemotherapy: is targeting circulating bone marrow derived endothelial progenitor cells the key? University Medical Center Utrecht, Department of Medical Oncology seminar, Utrecht, The Netherlands October, 2006
152. Antiangiogenic metronomic chemotherapy: markers, mechanisms and clinical application The Rudbeck Laboratory Vascular Biology Unit Seminar Series, Uppsala Sweden September, 2006
153. VEGF as a therapeutic target for antiangiogenic therapy: preclinical and clinical update Roche Avastin Breast Advisory Board meeting September, 2006
154. Antiangiogenic therapy for cancer using Avastin Roche Oncology GI meeting, Toronto September, 2006
155. Impact of endothelial progenitor cells in antiangiogenic drug mediated chemosensitization Keynote Lecture, 4th Annual Angiogenesis and Vascular Targeting Agents Drug Discovery & Development Summit September, 2006
156. Progress in the application of low dose metronomic antiangiogenic chemotherapy for the treatment of advanced metastatic disease Keynote Lecture, 2nd European Conference on Tumor Angiogenesis and Antiangiogenic Therapy September, 2006
157. Possibilities and applications of micro-ultrasound in small animal cancer research VisualSonics VIP In Vivo Tour, Toronto August, 2006
158. Antiangiogenic metronomic chemotherapy: markers and mechanisms in mice and men 21st Annual Offering of Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis: Biological Significance and Clinical Relevance June, 2006
159. Targeting VEGF: the receptor or the ligand? Forum of Excellence Antiangiogenesis in Breast and Lung Cancer, Discussion Workshop, Barcelona June, 2006
160. Angiogenesis basic science: an update on metronomic antiangiogenic therapy and VEGF” 1st Annual Biological Basis of Breast Cancer: Implications for Clinical Diagnosis and Treatment June, 2006
161. Targeting angiogenesis in cancer: the rationale Forum of Excellence – Antiangiogenesis in Breast and Lung Cancer, Barcelona Spain June, 2006
162. Rationale and potential advantages for using multitargeting antiangiogenic receptor tyrosine kinase inhibitors 20:20 Oncologist Forum Series - Investigating The New Generation of Small Molecule Kinase Inhibitors of Angiogenesis (online interactive series), Keynote Lecture June, 2006
163. Inhibition of angiogenesis – the next questions 8th International Symposium on Biological Therapy of Cancer: from Disease to Targeted Therapy June, 2006
164. Antiangiogenic basis for metronomic principles: preclinical data for UFT to suggest a possible role as metronomic chemotherapy MERCK - ASCO Metronomic Scientific Discussion, Atlanta June, 2006
165. Rationale and uses of simultaneous targeting of VEGF and PDGF receptors as an anti-cancer/antiangiogenic treatment strategy Pfizer Advisory Board Workshop, Atlanta June, 2006
166. Antiangiogenic therapy for cancer using Avastin Roche Canada - Overview of Angiogenesis and Anti-VEGF Theory, Toronto May, 2006
167. Antiangiogenic therapy using multi-targeting receptor tyrosine kinase inhibitors Pfizer - Conference on Angiogenesis, Caracas Venezuela May, 2006
168. Update on antiangiogenic therapy for cancer using bevacizumab the anti-VEGF antibody Roche Taiwan Satellite Meeting, Taipei, Taiwan May, 2006
169. Development and clinical application of the concept of metronomic antiangiogenic chemotherapy 11th Annual Meeting of Joint Cancer Society, Taipei, Taiwan May, 2006
170. Metronomic chemotherapy: from concept to clinical application for advanced metastatic disease Toronto-Sunnybrook Regional Cancer Centre, 1st Annual Cancer Research Day, Toronto May, 2006
171. Monitoring effects of antiangiogenic or vascular disrupting drugs preclinically using high frequency micro-ultrasound VisualSonics Scientific Advisory Board meeting April, 2006
172. Metronomic antiangiogenic chemotherapy for metastatic disease: concept and clinical application Moffitt Cancer Center Research Grand Rounds Series April, 2006
173. Conceptual basis and clinical application of antiangiogenic metronomic chemotherapy for treatment of metastatic disease The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2006: New Approaches to Cancer Prevention & Therapy, Baltimore April, 2006
174. Antiangiogenic drugs: moving rapidly to the forefront of cancer (chemo)therapy 96th Annual AACR meeting - In The Forefront of Advances in Cancer Research symposium, April, 2006
175. Antiangiogenic therapy for cancer: biologic principles and clinical outcomes Institute for Drug Development Grand Rounds, San Antonio March, 2006
176. Monitoring effects of antiangiogenic or vascular disrupting drugs preclinically using high frequency micro-ultrasound VisualSonics Scientific Advisory Board meeting March, 2006
177. Antiangiogenic therapy for cancer: biologic principles and clinical outcomes Arizona Cancer Center Grand Rounds, Tucson Arizona March, 2006
178. Translating metronomic antiangiogenic chemotherapy into the clinic Sidney Kimmel Cancer Center 2006 Conference on Proteogenomics for Diagnosis, Imaging and Therapy of Cancer March, 2006
179. Metronomic antiangiogenic chemotherapy: preclinical and clinical updates The University of Chicago Cancer Research Center monthly seminar series, Chicago February, 2006
180. Preclincal and clinical studies of low dose metronomic (antiangiogenic) chemotherapy for treatment of advanced metastatic disease The 2006 Miami Nature Biotechnology Winter Symposium: Angiogenesis in Cancer and Vascular Disease February, 2006
181. Metronomic chemotherapy: an update on recent preclinical and clinical studies The 8th Int’l Symposium on Anti-Angiogenic Agents, La Jolla February, 2006
182. VEGF as a therapeutic target for antiangiogenic therapy: preclinical and clinical update London Regional Cancer Centre Oncology Rounds, London Ontario January, 2006
183. Metronomic antiangiogenic chemotherapy: markers and mechanisms in mice and men AACR Special Conference on Cancer, Proteases, and the Tumor Microenvironment, Bonita Springs December, 2005
184. An update on antiangiogenic therapy for cancer with emphasis on VEGF as a target 2005 Annular Convention of the Society of Colon and Rectal Surgeons, Taipei, Taiwan, December, 2005
185. An update on antiangiogenic therapy for cancer with emphasis on VEGF as a target Koo Foundation Sun Yet-Sen Cancer Center, Taipei, Taiwan December, 2005
186. Progress in combinatorial antiangiogenic metronomic chemotherapy: from mice to men and back University of Hong Kong, Centre for Cancer Research, Hong Kong, China December, 2005
187. CEPs, CECs, and sVEGFR-2 as antiangiogenic drug biomarkers Novartis PTK/ZK Biomarker Development Advisory Board Meeting, Philadelphia November, 2005
188. Circulating VEGFR-2+ endothelial (progenitor) cells to establish optimal biologic dose for metronomic chemotherapy and targeted antiangiogenic drugs AACR Special Conference on Antiangiogenesis and Drug Delivery to Tumors: Bench to Bedside and Back, Waltham November, 2005
189. Clinical translation of metronomic antiangiogenic chemotherapy: markers and mechanisms MD Anderson Cancer Center, Dept. of Cancer Biology s Cancer Metastasis Research Program Seminar Series, Houston November, 2005
190. Metronomic antiangiogenic chemotherapy: from the bench to clinical bedside and back Sunnybrook & Women’s College Health Sciences Centre, Dept. of Molecular and Cellular Biology Research 1st Annual Retreat, Collingwood November, 2005
191. Antiangiogenic Therapy of Cancer Sunnybrook & Women s Foundation Fellowship Society Donor Forum Take a Chair for Canada s Best November, 2005
192. Some thoughs on the (best) use of antiangiogenic drugs – especially multitargeted RTKIs – for treatment of kidney cancer Princess Margaret Hospital/Ontario Cancer Institute GU Tumor Board November, 2005
193. Antiangiogenic metronomic chemotherapy for cancer: from bench to bedside and back McPeak Lecture, Memorial Sloan-Kettering Cancer Center, the 30th Annual Alumni Society Meeting Shifting Paradigms in Solid Tumor Oncology November, 2005
194. Emerging cellular biomarkers to monitor antiangiogenic drug activity and optimal dosing Genentech BioOncology Angiogenesis Summit, Philadelphia November, 2005
195. VEGF as a therapeutic target for antiangiogenic therapy: preclinical and clinical update Queen Elizabeth II Medical Rounds October, 2005
196. Markers and mechanisms for metronomic antiangiogenic chemotherapy in mouse and man International Conference -Tumor-host interaction and angiogenesis: basic mechanisms and therapeutic perspectives October, 2005
197. Markers and mechanisms for metronomic antiangiogenic chemotherapy in mouse and man NCRI Cancer Conference, Birmingham October, 2005
198. Aantiangiogenic therapy for cancer using Avastin Roche Head Office Avastin Launch Week, Roche Canada, Mississauga October, 2005
199. Antiangiogenic low-dose metronomic chemotherapy: markers and mechanisms The 15th International Symposium of the Hiroshima Cancer Seminar Foundation Current Progress of Cancer Chemotherapy, Hiroshima, October, 2005
200. An update on antiangiogenic cancer therapy (with emphasis on VEGF as a target Roche Life Convention 2005, Panama City, Panama September, 2005
201. An update on antiangiogenic cancer therapy Princess Margaret Hospital Radiation Oncology Dept. 2005 Summer of Science Series - An Overview of Targeted Anti-CancerTherapies August, 2005
202. VEGF as a key target for antiangiogenic therapy of cancer Vineland Estates Medical Oncology Lecture, Vineland Estates July, 2005
203. Role of anti-angiogenesis and VEGF therapy 2005 Pan Asia Pacific Oncology Summit, Chiba July, 2005
204. Antiangiogenic chemotherapy: markers and mechanisms in mouse and man Harvard Medical School Department of Continuing Education and Massachusetts General Hospital, 19th Annual Course on Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis June, 2005
205. VEGF as a key target for antiangiogenic therapy of cancer North Eastern Ontario Regional Cancer Centre Combined Oncology Rounds June, 2005
206. Antiangiogenic metronomic chemotherapy for cancer: from bench to bedside and back 2005 Chappel Memorial Lecture, University of Guelph June, 2005
207. VEGF as a key target for antiangiogenic therapy of cancer 9th Annual ACOG Symposium, Stanley Bridge, Prince Edward Island June, 2005
208. Translational aspects of antiangiogenic therapy using targeted agents and metronomic chemotherapy Richard T Israels Distinguished Lecture, BC Cancer Agency June, 2005
209. Targeted angiogenesis (with emphasis on breast cancer) 7th Milan Breast Cancer Conference June, 2005
210. VEGF as a key target for antiangiogenic therapy of cancer William Osler Health Centre – Peel Memorial Hospital, Brampton May, 2005
211. 2005 ASCO Annual Meeting: Integrated Education Session on Putting Antiangiogenic Therapy into Practice Juravinski Cancer Centre Regional Oncology Rounds, Hamilton, May, 2005
212. Discussion of abstract no. 5000 (A. Garcia et al.) and the concept of metronomic chemotherapy 2005 ASCO Annual Meeting: Integrated Education Session on Putting Antiangiogenic Therapy into Practice May, 2005
213. VEGF as a key target for antiangiogenic therapy of cancer Ottawa Regional Cancer Centre, Ottawa May, 2005
214. Pharmacodynamic biomarkers for targeted antiangiogenic drugs, or metronomic chemotherapy Wyeth Pharmaceuticals, Pearl River NY May, 2005
215. Rapid increases in circulating TGFa as a PD biomarker for anti-EGFR antibodies? EGFR Summit, Boca Raton FL April, 2005
216. Epigenetic aspects of environmentally mediated multicellular drug resistance 96th Annual AACR Meeting Educational Session: Drug Resistance in Solid Tumors April, 2005
217. Molecular and cellular surrogate markers for antiangiogenic drug activity and optimal therapeutic dosing 96th AACR Annual Meeting - Symposium on Bio-sensors and the Signatures of Angiogenic Tumor Vasculature: Tools for Early Detection and Monitoring Therapeutic Responses April, 2005
218. Tumor angiogenesis and antiangiogenic therapy (for breast cancer University of Toronto MBP 1018Y Oncology Course 2005 April, 2005
219. VEGF as a key target for antiangiogenic therapy of cancer Tumor angiogenesis and antiangiogenic therapy (for breast cancer April, 2005
220. VEGF as a key target for antiangiogenic therapy of cancer Roche Regional Advisory Board Meeting (Ontario/East Coast April, 2005
221. Introduction to VEGF and the rationale and mode of action of Avastin Roche Canada Investigator Meeting March, 2005
222. Preclinical and clinical aspects of metronomic/antiangiogenic chemotherapy: markers and mechanisms CovX, San Diego March, 2005
223. Metronomic/antiangiogenic chemotherapy: markers and mechanisms Amgen Inc., Thousand Oaks March, 2005
224. VEGFR-2+ circulating peripheral blood cells as surrogate markers for antiangiogenic drug activity and dosing 7th International Symposium on Antiangiogenic Agents, La Jolla CA February, 2005
225. Recent developments in antiangiogenic drug and vascular disrupting agent research BioCEO & Investor Conference, New York City February, 2005
226. Metronomic chemotherapy as efficacious but non toxic strategy 13th Tokyo Cancer Chemotherapy Symposium, Tokyo Japan February, 2005
227. Cellular and molecular basis for antiangiogenesis mediated by low dose metronomic chemotherapy 2005 NIEHS Distinguished Lecture Series, National Institutes of Environmental Health Sciences, N. Carolina February, 2005
228. Recent advances in colorectal cancer and other solid tumors: angiogenesis inhiibitors Hoffmann-La Roche National Sales Meeting February, 2005
229. Antiangiogenic low-dose metronomic chemotherapy: markers and mechanisms Loeb Seminar Series, Ottawa Health Research Institute January, 2005
230. VEGF as an emerging target for antiangiogenic therapy of cancer” Recent Advances in Colorectal Cancer and Other Solid Tumors: Angiogenesis Inhiibitors Karmanos Cancer Institute/Wayne State University January, 2005
231. Targeting the vasculature of early stage breast cancer using metronomic chemotherapy/targeted drug combinations 9th St. Gallen International Breast Cancer Conference: Primary Therapy for Early Breast Cancer January, 2005
232. VEGF as a key target for antiangiogenic therapy of cancer Roche Canada, Toronto, December, 2004
233. Antiangiogenic low-dose metronomic chemotherapy: markers and mechanisms VEGF as a key target for antiangiogenic therapy of cancer December, 2004
234. Some emerging principles of low-dose metronomic chemotherapy Johnson & Johnson, Springhouse December, 2004
235. Chemotherapy Foundation Symposium XXII, Innovative Chemotherapy for Tomorrow, New York City Chemotherapy Foundation Symposium XXII, Innovative Chemotherapy for Tomorrow, New York City November, 2004
236. VEGF as an emerging target for antiangiogenic therapy of cancer Recent Advances in Colorectal Cancer: Angiogenesis Inhiibitors, Penn State Milton S. Hershey Medical Center Grand Round November, 2004
237. Surrogate pharmacodynamic markers for establishing optimal antiangiogenic drug dose and activity 2nd International Symposium on Angiogenesis and Cancer, Malaga Spain, November, 2004
238. Molecular and cellular basis for antiangiogenesis mediated by low-dose metronomic chemotherapy International Conference on Tumor Progression and Therapeutic Resistance, Philadelphia November, 2004
239. Antiangiogenic therapeutics: improving the chances of success with surrogate markers Keynote lecture: University of Toronto, Department of Medical Biophysics Retreat, Couchiching Ontario October, 2004
240. Preclinical studies of low-dose metronomic UFT chemotherapy as an efficacious but non-toxic treatment strategy 42nd Annual Meeting of the Japan Soceity of Clinical Oncology October, 2004
241. Circulating VEGFR-2+ cells as surrogate markers to establish optimal dosing for antiangiogenic drugs and metronomic chemotherapy Keynote lecture, 1st European Conference on Tumor Angiogenesis and Antiangiogenic Therapy, Munich Germany October, 2004
242. Surrogate markers for establishing optimal biologic dose of antiangiogenic drugs and metronomic low dose chemotherapy Novartis Pharmaceuticals, Basel Switzerland September, 2004
243. Surrogate markers for establishing optimal biologic dose of antiangiogenic drugs and metronomic low dose chemotherapy Tumor Biology Center, Karolinska Institute, Stockholm Sweden September, 2004
244. Chemotherapy as antiangiogenesis: a rationale for inhibiting the VEGF pathway in combination with conventional chemotherapeutic agents F. Hoffmann-La Roche Ltd., Avastin Forum of Excellence, Amsterdam, the Netherlands September, 2004
245. Metronomic basis for anti-angiogenic therapy Gordon Research Conference on Cancer: Models & Mechanisms, Newport August, 2004
246. Surrogate biomarkers for optimizing metronomic/antiangiogenic chemotherapy regimens IBC’s 9th Annual World Congress – Drug Discovery Technology 2004, Boston August, 2004
247. Surrogate markers to determine optimal biologic dose for metronomic chemotherapy and other antiangiogenic drugs Anti-Cancer Drug Discovery & Development Summit, Philadelphia July, 2004
248. Rationale and biology of antiangiogenic therapy: an update National Surgical Adjuvant Breast and Bowel Project meeting June, 2004
249. Combating drug resistance and toxicity with metronomic chemotherapy and targeted antiangiogenics Harvard Medical School Department of Continuing Education and Massachusetts General Hospital, 19th Annual Course on Critical Issues in Tumor Microcirculation June, 2004
250. Southwest Oncology Group Breast Cancer Correlative Sciences Committee meeting Southwest Oncology Group Breast Cancer Correlative Sciences Committee meeting May, 2004
251. Tumor spheroids as in vitro models to screen and assess anti-cancer drug activity and study resistance Chiron Corporation, San Francisco May, 2004
252. Oral low dose metronomic chemotherapy as an effective antiangiogenic treatment strategy Japanese Association for Molecular Targeted Therapy of Cancer, Kagoshima May, 2004
253. Molecular basis for antiangiogenesis mediated by low-dose metronomic chemotherapy University of Kentucky Distinguished Visitor Seminar Program, Lexington April, 2004
254. Antiangiogenic therapy the way(s) ahead 95th AACR Annual Meeting Meet-the-Expert Sunrise Session, Orlando March, 2004
255. Molecular and cellular basis of angiogenesis inhibition mediated by low-dose metronomic chemotherapy Inaugural Kimmel Cancer Conference 2004: Genomics, Signaling and Tumor Targeting, San Diego, California February, 2004
256. Molecular and cellular basis of angiogenesis inhibition mediated by low-dose metronomic chemotherapy Compound Therapeutics, Inc., Boston February, 2004
257. Molecular and cellular basis of angiogenesis inhibition mediated by low-dose metronomic chemotherapy Memorial Sloan-Kettering Cancer Center, Molecular Pharmacology & Chemistry Seminar Series February, 2004
258. Surrogate markers for antiangiogenic drugs Targeted Therapies for the Treatment of Lung Cancer Investigators’ Meeting, San Diego, California February, 2004
259. Molecular and cellular basis of angiogenesis inhibition mediated by low-dose metronomic chemotherapy Wyeth-Ayerst Research Oncology Seminar, Pearl River, NY January, 2004
260. Molecular and cellular basis for the antiangiogenic effects of low-dose metronomic chemotherapy PTC Therapeutics, Inc., New York January, 2004
261. Molecular and cellular basis for the antiangiogenic effects of low-dose metronomic chemotherapy New York Academy of Sciences: Anti-Angiogenic Therapeutic Approaches to Treating Cancer: The Perspective in 2004 January, 2004
262. Molecular and cellular basis for the antiangiogenic effects of low-dose metronomic chemotherapy 2004 Keystone Symposium on Angiogenesis: Novel Basic Science Insights and Human Therapy, Santa Fe January, 2004
263. State of the art review: tumor angiogenesis Novartis Pharmaceuticals PTK Primary Investigators’ Meeting January, 2004
264. Antiangiogenic mechanism of low-dose metronomic chemotherapy 6th International Symposium on Anti-Angiogenic Agents: Recent Advances and Future Directions in Cell Biology and Clinical Research, La Jolla, California January, 2004
265. The cellular and molecular basis for antiangiogenesis mediated by low-dose metronomic chemotherapy: preclinical and clinical aspects The 2003 International Workshop of Angiogenesis Research in Taiwan, Taipei, Taiwa December, 2003
266. Challenges for clinical translation of angiogenesis inhibitors The American Society of Hematology, 45th Annual Meeting – Targeting the Endothelium for Good and Bad, San Diego December, 2003
267. Antiangiogenic metronomic chemotherapy: role of tsp-1 and circulating endothelial progenitor cells Chemical and Genetic Regulation of TSP Anti-Angiogenesis symposium, Abbott Laboratories, Chicago December, 2003
268. Molecular and cellular basis of angiogenesis inhibition mediated by low-dose metronomic chemotherapy Dana-Farber Cancer Institute Seminars in Oncology Tischler Lecture December, 2003
269. Role of angiogenesis in tumor development Genentech BioOncology Solid Tumor Investigators November, 2003
270. Molecular and cellular aspects for the antiangiogenic effects of low dose metronomic chemotherapy University of Pennsylvania Hematology/Oncology Research Seminar Series November, 2003
271. Frequent low-dose metronomic chemotherapy as a potential antiangiogenic strategy to treat drug resistant and metastatic tumors Japan Society of Clinical Oncology 41st Annual Meeting, Sapporo October, 2003
272. Frequent low-dose metronomic chemotherapy as a potential antiangiogenic strategy to treat drug resistant and metastatic tumors Taiho Pharmaceuticals Co. Ltd., Tokyo, Japan October, 2003
273. VEGF - An emerging target for anticancer therapy Barbara Ann Karmanos Cancer Institute, Detroit October, 2003
274. Metronomic chemotherapy: molecular mechanisms and integration with antiangiogenic agents or trastuzumab 3rd International Symposium on Translational Research in Oncology October, 2003
275. Cellular and molecular basis for the selective antiangiogenic effects of frequent low-dose (metronomic) chemotherapy The 31st Meeting of the International Society for Oncodevelopmental Biology and Medicine – From Tumor Biology to Clinical Oncology September, 2003
276. Inhibition of angiogenesis a single agent approach? 7th International Meeting and 1st World Congress Biotherapy of Cancer, From Disease to Targeted Treatment September, 2003
277. Molecular and cellular basis for the selective antiangiogenic effects of low-dose metronomic chemotherapy European Institute of Oncology, Milan, Italy July, 2003
278. Cellular and molecular basis for the selective antiangiogenic effects of frequent low-dose (metronomic) chemotherapy 4th Symposium on the Biology of Endothelial Cells, Munich, Germany July, 2003
279. Molecular and cellular basis for the selective antiangiogenic effects of low-dose metronomic chemotherapy Novartis Pharma AG, Basel, Switzerland July, 2003
280. Molecular and cellular aspects for the antiangiogenic effects of low dose metronomic chemotherapy: preclinical and clinical aspects The 2003 Annual Retreat on Cancer Research in New Jersey, Princeton June, 2003
281. Overcoming drug resistance in cancer Harvard Medical School Department of Continuing Education and Massachusetts General Hospital, 18th Annual Offering of Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis, Biological Significance and Clinical Relevance Workshop June, 2003
282. Angiogenesis and cancer SociJtJ des sciences vasculares du QuJbec Thombose et Cancer Apres-midi ConfJrence, Montreal June, 2003
283. Preclinical and clinical studies of frequent low-dose (metronomic) antiangiogenic chemotherapy to treat drug resistant metastatic disease AACR workshop Molecular Biology in Clinical Oncology June, 2003
284. Molecular and cellular aspects for the antiangiogenic effects of low-dose metronomic chemotherapy: preclinical and clinical aspects IDEC Pharmaceuticals, San Diego June, 2003
285. Low-dose metronomic antiangiogenic chemotherapy: preclinical and clinical applications in breast cancer University of Toronto Breast Cancer Symposium 2003 – Advances in Breast Cancer: From Molecular Pathology & Imaging to Therapeutics June, 2003
286. Cellular and molecular basis for the selective antiangiogenic effects of metronomic low dose chemotherapy National Cancer Institute Vascular Biology Faculty Retreat, Washington DC May, 2003
287. Antiangiogenic drugs and vascular targeting agents 14th Annual Cancer Progress Conference, New York March, 2003
288. Metronomic antiangiogenic therapy for metastatic disease 44th Annual Clinical Conference: Molecular Therapeutics for Cancer Metastasis, Houston March, 2003
289. Preclinical and clinical studies of metronomic low-dose antiangiogenic chemotherapy MOBIX Seminar, McMaster University, Hamilton, Ontario March, 2003
290. Developing Better Models and Markers for (VEGF / VEGFR-2) Targeted Therapies AACR Special Workshop Lessons Learned: Translational Issues for Targeted Drug Development March, 2003
291. Antiangiogenic treatment strategies for the treatment of metastatic breast cancer 7th Annual Breast Cancer Symposium – Metastases: Mechanism of Formation; Identification of Characterization February, 2003
292. Current status of antiangiogenic treatment strategies for cancer – the promise and the problems Medical Grand Rounds, Sunnybrook and Womens College Health Sciences Centre February, 2003
293. Molecular, cellular and clinical aspects of low-dose metronomic antiangiogenic chemotherapy Dean s Seminar, Drexel University College of Medicine February, 2003
294. Preclinical and clinical studies of metronomic low-dose antiangiogenic chemotherapy CombinatoRx, Inc., Boston February, 2003
295. Overview of the preclinical and clinical status of antiangiogenic drugs OSI Pharmaceuticals, Inc., New York February, 2003
296. Preclinical and clinical studies of metronomic low-dose antiangiogenic chemotherapy of metastatic cancer University of Toronto, Department of Laboratory Medicine and Pathobiology Seminar Series, Toronto January, 2003
297. Overview of angiogenesis in lung cancer 3rd Annual Opinion Leader Summit: Targeted Therapies for the Treatment of Lung Cancer, Aspen January, 2003
298. Molecular markers of angiogenic efficacy 5th International Symposium on Anti-Angiogenic Agents –Recent Advances and Future Directions in Cell Biology and Clinical Research January, 2003
299. Molecular, cellular and clinical aspects of low-dose metronomic antiangiogenic chemotherapy St. Jude Children s Research Hospital, Memphis January, 2003
300. Chemotherapy and cancer: the less the better? 81st Annual Beaumont Lecture, Wayne County Medical Society November, 2002
301. Antiangiogenic metronomic chemotherapy: preclinical and clinical aspects Society for Biology Therapy 17th Annual Meeting November, 2002
302. Continuous low-dose (metronomic) antiangiogenic chemotherapy: preclinical and clinical update University of Minnesota, Department of Laboratory Medicine and Pathology Grand Rounds November, 2002
303. Continuous low-dose (metronomic) antiangiogenic chemotherapy: preclinical and clinical update 39th Annual AndrJ Aisenstadt Memorial Clinical Day, The Sir Mortimer B. Davis – Jewish General Hospita October, 2002
304. Antiangiogenesis: molecular pathways and strategies Genentech Pathology Advisory Board Meeting October, 2002
305. Integrating targeted antiangiogenic drugs with low-dose metronomic chemotherapy: preclinical and clinical update Genentech Bio-oncology, San Francisco October, 2002
306. Overview on angiogenesis 2002 Genentech Solid Tumor Investigators Meeting, Scottsdale September, 2002
307. Metronomic/antiangiogenic low-dose chemotherapy: rationale and preclinical/clinical update H. Lee Moffitt Cancer Center and Research Institute, Tampa September, 2002
308. Chemotherapy and cancer is less more? An angiogenic perspective Queen's University, Kingston September, 2002
309. Molecular and cellular mechanisms of low-dose metronomic/antiangiogenic chemotherapy: preclinical and clinical update Abbott Laboratories, Chicago July, 2002
310. Angiogenesis overview rationale for targeting VEGF/VEGFR ICMIC/SAIRP Investigators Meeting, National Institutes of Health, USA, Herndon July, 2002
311. Maximizing the benefits of antiangiogenic drugs by combination with continuous low-dose (metronomic) chemotherapy AACR workshop Molecular Biology in Clinical Oncology Aspen July, 2002
312. Advantages of integrating chemotherapy given in the low-dose metronomic fashion with antiangiogenic drugs 2nd Annual International Symposium on Translational Research in Oncology June, 2002
313. Maximizing the benefits of antiangiogenic drugs by combination with continuous low-dose (metronomic) chemotherapy 17th Meeting of the European Association for Cancer Research, Merck – Satellite Symposium: Emerging Biotherapy of Cancer June, 2002
314. Maximizing the benefits of antiangiogenic drugs by combination with continuous low-dose (metronomic) chemotherapy Harvard Medical School Department of Continuing Education and Massachusetts General Hospital, 17th Annual Offering of Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis, Biological Significance and Clinical Relevance Workshop June, 2002
315. A rationale for combining vascular targeting with antiangiogenic agents Vascular Targeting A New Class of Cancer Therapeutics Session, BIO 2002 International Biotechnology Convention & Exhibition June, 2002
316. A rationale for combining vascular targeting with antiangiogenic agents 1st International Conference on Vascular Targeting, Boston June, 2002
317. What are the molecular targets for stopping blood vessel growth in cancer? A Media Summit Antiangiogenic Therapy of Cancer : Putting The Pieces into Perspective, The Angiogenesis Foundation May, 2002
318. Preclinical and clinical studies of continuous low-dose (metronomic) antiangiogenic chemotherapy for the treatment of drug resistant cancers Duke University Medical Center, Brain Tumor Seminar Series May, 2002
319. Continuous low-dose (metronomic) antiangiogenic chemotherapy for the treatment of drug resistant cancers University of Columbia, New York April, 2002
320. Preclinical and clinical studies of continuous low-dose (metronomic) antiangiogenic chemotherapy for the treatment of drug resistant cancers B.C. Cancer Agency April, 2002
321. Continuous low-dose (metronomic) antiangiogenic chemotherapy: preclinical and clinical update Regeneron Pharmaceuticals, Inc., Tarrytown, New York April, 2002
322. Preclinical and clinical studies on combination metronomic antiangiogenic chemotherapy Canadian Association of Medical Oncology lecture Montreal April, 2002
323. Preclinical and clinical studies of low-dose metronomic anti-angiogenic chemotherapy for the treatment of drug resistant tumors Children Hospital Los Angeles Research Institute s Distinguished Lecture Series, Los Angeles March, 2002
324. Integrating anti-KDR/flk-1 antibodies with low-dose metronomic chemotherapy ImClone Systems, Inc. Anti-KDR Advisory Board Meeting, Scottsdale March, 2002
325. Metronomic antiangiogenic chemotherapy: genetic and epigenetic mechanisms governing long term response and resistance 2002 Keystone Symposium on Angiogenesis in Cancer and Other Diseases: From Genes to Function to Therapy February, 2002
326. Chemotherapy and angiogenesis inhibitors 4th International Symposium on Anti-Angiogenic Agents – Recent Advances and Future Directions in Cell Biology and Clinical Research January, 2002
327. Anti-angiogenic/metronomic chemotherapy: from bench to bedside Millennium Pharmaceuticals, Inc December, 2001
328. Combination anti-angiogenic/metronomic chemotherapy: from bench to bedside Pfizer Lecture, Clinical Research Institute of Montreal, Montreal December, 2001
329. Demonstrating the principle of combining metronomic chemotherapy with investigational anti-angiogenic drugs Banbury Center Workshop on New Concepts for Clinical Cancer Trials - Chemotherapy, angiogenesis inhibitors, and the lessons of mouse models”, Cold Spring Harbor November, 2001
330. Anti-angiogenic/metronomic chemotherapy: from bench to bedside The Alberta Cancer Board Annual Conference, Banff, Alberta November, 2001
331. Future role of targeting epidermal growth factor receptor in breast cancer therapy Oncology Nursing Society CNE Satellite Symposium: Emerging Treatment Options in Advanced Breast Cancer November, 2001
332. Results in animal models, or clinical trials/experiences Banbury Center Workshop on New Concepts for Clinical Cancer Trials - Chemotherapy, angiogenesis inhibitors, and the lessons of mouse models”, Cold Spring Harbor November, 2001
333. Treating malignant cancers using chemoprevention-like treatment strategies: the metronomic anti-angiogenic chemotherapy concept Merck Special Satellite Symposium on COX-2 and Cancer, Nashville, Tennessee October, 2001
334. Treating malignant cancers using chemoprevention-like treatment strategies: the metronomic anti-angiogenic chemotherapy concept Plenary lecture at the Seventh International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases, Nashville, Tennessee October, 2001
335. Anti-angiogenic drugs as a new therapeutic approach for cancer JP Morgan H & Q and Cold Spring Harbor Laboratory Executive Conference, Cold Spring Harbor October, 2001
336. Oral non-toxic metronomic/antiangiogenic chemotherapy for drug-resistant carcinomas CaP CURE Eighth Annual Scientific Retreat retreat, Lake Tahoe, Nevada September, 2001
337. Is anti-angiogenic therapy a valid - and promising - treatment for cancer? Princess Margaret Hospital Conference: New Developments in Cancer Management September, 2001
338. Anti-angiogenic/metronomic chemotherapy as a treatment strategy for multidrug-resistant tumors Seventh Annual Jaffar Oncology Conference, Strategies for a Cure: Targeted Innovations for the 21st Century, Dearborn, Michigan September, 2001
339. Exploiting chemotherapeutic drugs as anti-angiogenics: the combination Ëœmetronomicâ„¢ therapy concept Stanford Angiogenesis Research Forum, Stanford University Medical Center September, 2001
340. Combination anti-angiogenic drug low dose metronomic chemotherapy Gordon Research Conference - Angiogenesis and Microcirculation, Newport, Rhode Island August, 2001
341. Low-dose anti-angiogenic (metronomic) chemotherapy as a chronic, non-toxic strategy to treat drug resistant cancer AACR workshop Molecular Biology in Clinical Oncology, Aspen July, 2001
342. Chemotherapeutic agents as anti-angiogenics 1st International Symposium on Translational Research in Oncology: Recent Advances and Future Directions in Breast and Ovarian Cancers July, 2001
343. Combination metronomic chemo/anti-angiogenic agent therapy of drug-resistant cancers Royal College Lecture, Canadian Urological Association 2001 Annual Meeting, Toronto, Ontario June, 2001
344. Overcoming drug resistance in cancer Harvard Medical School Department of Continuing Education and Massachusetts General Hospital, 16th Annual Offering of Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis, Biological Significance and Clinical Relevance Workshop June, 2001
345. Anti-angiogenic therapy of cancer: opportunities and problems 11th New England Doppler Conference, Lake Rosseau, Ontario June, 2001
346. Anti-angiogenic agents in development Ontario Clinical Oncology Group Metastatic Breast Cancer Retreat, Toronto, Ontario June, 2001
347. Combination antiangiogenic drug treatment for drug resistant tumors: integration with metronomic chemotherapy Wyeth-Ayerst Research, Pearl River June, 2001
348. Therapeutic implications of the link between oncogenes and tumor angiogenesis Visiting Professor Lecture, Division of Surgery, MD Anderson Cancer Center, Houston May, 2001
349. Low-dose anti-angiogenic (metronomic) chemotherapy strategies for treatment of multidrug resistant tumors Visiting Professor Lecture, Cancer Biology - Angiogenesis Group, MD Anderson Cancer Center May, 2001
350. Combination anti-angiogenic drug low dose metronomic chemotherapy Department of Pathology Grand Rounds Seminar, Beth Israel Deaconess Medical Center, Boston May, 2001
351. Antiangiogenic/metronomic chemotherapy of multidrug resistant tumors Chiron Corporation - Basic Science Seminar Series, San Francisco, California May, 2001
352. The future of antiangiogenesis therapeutic research Clinical Trials for Antiangiogenic Therapy of Cancer - Issues, Problems and Solutions Expert Panel Symposium May, 2001
353. Combination anti-angiogenic drug/low dose (metronomic) chemotherapy of cancer: preclinical and clinical aspects 63rd Course: Angiogenesis and Signal Transduction in Anti-Cancer Drug Development, International School of Pharmacology, Erice, Sicily April, 2001
354. Development of a non-toxic, metronomic anti-angiogenic chemotherapy strategy to treat drug-resistant tumors: results using human tumor xenografts in immune-deficient mice Mouse Physiology Group Seminar, Samuel Lunenfeld Research Institute, Toronto April, 2001
355. Metronomic anti-angiogenic chemotherapy as a non-toxic strategy to treat drug-resistant tumors: preclinical and clinical update Ottawa Regional Cancer Centre, Ottawa April, 2001
356. Anti-angiogenic (metronomic) chemotherapy: preclinical and clinical update The University of Missouri-Ellis Fischel Cancer Center and School of Medicine Multidisciplinary Oncology Grand Rounds, Columbia April, 2001
357. On the concept of low-dose metronomic anti-angiogenic chemotherapy Tumor Angiogenesis meeting sponsored by AstraZeneca AS, Oslo, Norway February, 2001
358. Low dose metronomic chemotherapy in relation to anti-angiogenesis S an update Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York December, 2000
359. Continuous anti-angiogenic drug low dose chemotherapy: preclinical and clinical update Cutaneous Biology Research Center, Massachusetts General Hospital, Boston December, 2000
360. Anti-angiogenic drug/low dose metronomic combination chemotherapy: preclinical and clinical update Symposium on Tumor Angiogenesis: From Bench to Bedside, Freiburg November, 2000
361. Low dose metronomic anti-angiogenic combination chemotherapy Aventis/GenCell meeting on Angiogenesis in Disease”, Paris November, 2000
362. The concept of continuous low-dose (metronomic) anti-angiogenic chemotherapy 11th NCI-EORTC-AACR Symposium on New Drugs in Development for Cancer, Amsterdam The Netherlands November, 2000
363. On the concept of low dose metronomic anti-angiogenic chemotherapy First Pediatric Neuro-Oncology Symposium, Hospital for Sick Childre October, 2000
364. Exploiting metronomic chemotherapy and the survival function of VEGF as a chronic anti-angiogenic strategy to treat drug resistant cancers AACR Special Conference Angiogenesis and Cancer: From Basic Mechanisms to Therapeutic Applications, Traverse City October, 2000
365. The concept of continuous low dose metronomic anti-angiogenic chemotherapy 11th International Conference - Chemical Modifiers of Cancer Treatment Series, Banff, October, 2000
366. Continuous low dose (metronomic) chemotherapy in combination with anti-VEGFR2 (flk-1/KDR) antibodies as a possible ‘resistance free’ non-toxic therapy to treat cancer VIIIth International Congress of the Metastasis Research Society, London, UK, September, 2000
367. On the concept of low dose metronomic anti-angiogenic chemotherapy CaP CURE Seventh Annual Scientific Retreat, Lake Tahoe, Nevada, September, 2000
368. Chemotherapeutic drugs as angiogenesis inhibitors Epithelial-Stromal Interactions and Tumor Progression Workshop, Bethesda, MD September, 2000
369. Development of anti-angiogenic drugs HSBC Securities (Canada) Inc. Oncology Symposium September, 2000
370. What are the most promising areas for new drug development in cancer? Amgen, Inc., Los Angeles September, 2000
371. Anti-angiogenic therapy of cancer: recent advances and problems to overcome Keynote Lecture, Society for Ultrasound in Biology and Medicine meeting, Windemere House September, 2000
372. The concept of continuous low dose metronomic anti-angiogenic chemotherapy American Association for Cancer Research/AstraZeneca Summit, Manchester September, 2000
373. The concept of continuous low dose metronomic anti-angiogenic chemotherapy Merck & Company, Philadelphia September, 2000
374. Exploring Low Dose Chemotherapy as an Anti-Angiogenic Therapy BioChem Pharma, Laval August, 2000
375. Signal Transduction Inhibitors and Chemotherapy as Possible Anti-angiogenic Drugs: Relationship to Acquired Drug Resistance AACR workshop "Molecular Biology in Clinical Oncology, Aspen, Colorado July, 2000
376. Two Different Approaches to Overcome Drug Resistance in Cancer Harvard Medical School Department of Continuing Education and Massachusetts General Hospital, 15th Annual Offering of Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis, Biological Significance and Clinical Relevance Workshop, Cambridge, June, 2000
377. Exploring Low Dose Chemotherapy as an Anti-Angiogenic Therapy Keynote Lecture, Era of Hope, Department of Defense (DOD) Breast Cancer Research Program (BCRP) Meeting June, 2000
378. Circumventing Acquired Drug Resistance and Severe Host Toxicity Using Continuous/Low Dose (Metronomic) Chemotherapy In Combination With an Anti-Angiogenic Drug Bridging the Strait of Georgia Conference, Victoria, British Columbia May, 2000
379. Tumor Angiogenesis: Underlying Principles and Potential as a Therapeutic Target Lecture given as The Eppley Visiting Professor at the 10th Annual Short Course in Cancer Biology, The Eppley Institute for Research in Cancer and Allied Diseases at the University of Nebraska Medical Center May, 2000
380. Exploiting Metronomic Chemotherapy and the Survival Function of VEGF as a Chronic Anti-Angiogenic Strategy to Treat Drug Resistant Cancers AACR Special Conference Melanoma: Basic Biology and Immunological Approaches to Therapy”, The Woodlands May, 2000
381. Exploiting Conventional Chemotherapeutic Drugs in Anti-Angiogenic Therapy of Cancer Canadian Association of Medical Oncologists 2000 Annual Meeting, Toronto, April, 2000
382. A Novel, Non-Toxic, Anti-Angiogenic Treatment Strategy Based on Continuous Low Dose Chemotherapy Wyeth-Ayerst Research, Pearl River March, 2000
383. Tumor Vaccines In Relationship To Anti-Angiogenic Therapy Aventis Pasteur Cancer Vaccine Network Annual Symposium, Toronto February, 2000
384. Continuous Low Dose Chemotherapy in Combination with Anti-VEGF Receptor-2 Antibodies as an Effective Long Term Anti-Angiogenic Treatment Strategy 2nd International Symposium on Anti-Angiogenic Agents January, 2000
385. Signal Transduction Inhibitors and Chemotheapeutic Drugs as Anti-Angiogenic Agents: Relationship to Drug Resistance The New York Academy of Medicine S Angiogenesis Conference, New York January, 2000
386. A Novel Anti-Angiogenic, Chemotherapy Based Treatment Strategy Capable of Causing Sustained Tumor Regressions in the Absence of Toxicity Toronto-Sunnybrook Regional Cancer Centre Lymphoma Rounds, Toronto January, 2000
387. Anti-Angiogenesis is a Means of Circumventing Acquired Drug Resistance: Different Experiences using Signal Transduction Inhibitors and Chemotherapeutic Drugs RPR Gencell, Hayward December, 1999
388. Links Between Oncogenes, Tumor Angiogenesis and Signal Transduction Inhibitor Therapy of Cancer CMIER Seminars in Biology and Chemistry, The Children Memorial Institute for Education and Research December, 1999
389. 'Accidental' Anti-Angiogenic Drugs: Signal Transduction Inhibitor and Chemotherapeutic Drugs as Examples Angiogenesis Workshop, Novartis Pharma AG, Basel November, 1999
390. Anti-Angiogenesis is a Means of Circumventing Acquired Drug Resistance: Different Experiences Using Signal Transduction Inhibitors and Chemotherapeutic Drugs Monsanto/Searle Discovery Pharmacology, St. Louis November, 1999
391. Circumventing Acquired Drug Resistance by Inhibiting Tumor Angiogenesis: Different Experiences using 'Anti-Oncogene' Signal Transduction Inhibitors or Conventional Chemotherapeutic Drugs Swiss Federal Institute of Technology, Zurich November, 1999
392. Functional and Therapeutic Linkages Between Oncogenes and Tumor Angiogenesis European School of Oncology, Symposium on Biological Basis for Antiangiogenic Therapy, Milan November, 1999
393. Oncogenes and the Control of Tumor Angiogenesis: Antibodies to the EGF Receptor or Her-2 as Possible Anti-Angiogenic Drugs In Vivo 5th International Symposium on Biological Therapy of Cancer S From Basic Research to Clinical Application, Munich October, 1999
394. A New Strategy to Reverse the Intrinsic or Acquired Drug Resistant Phenotype of Prostate Cancer Utilizing Angiogenesis Inhibitors CaP CURE Sixth Annual Scientific Retreat, Lake Tahoe October, 1999
395. Oncogenes and the Control of Tumor Angiogenesis: Antibodies to the EGF Receptor or Her-2 as Possible Anti-Angiogenic Drugs In Vivo 1999 Meeting of the Institute of Human Virology, A Symposium on HIV-AIDS & Cancer Biology September, 1999
396. Anti-Oncogene Directed Signal Transduction Inhibitors as Anti-Angiogenic Drugs 1999 Joint Annual Meeting of The International Society of Paediatric Oncology & The American Society of Pediatric Hematology/Oncology September, 1999
397. Mouse Tumor Models for Anti-Cancer Drug Discovery: Current Status S and Future Opportunities for Improvement Abbott Laboratories, Chicago August, 1999
398. Targeting Tumor Angiogenesis: Opportunities, Recent Advances S and Possible Pitfalls DuPont Pharmaceuticals Company, North Billerica, Massachusetts July, 1999
399. AEstablishing a Basic and Therapeutic Link Between Oncogenes and Tumor Angiogenesis AACR workshop Molecular Biology in Clinical Oncology, Aspen July, 1999
400. Cell Adhesion and Multicellular Drug Resistance Harvard Medical School Department of Continuing Education and Massachusetts General Hospital, 14th Annual Offering of Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis, Biological Significance and Clinical Relevance Workshop June, 1999
401. Anti-angiogenic Drug for the Treatment of Cancer: An Update COMET 1999 Meeting, Gravenhurst, Ontario June, 1999
402. Implications of Establishing a Link Between Oncogenes and Tumor Angiogenesis Angiogenesis Symposium - Annual Health Research Day, University of Manitoba, Winnipeg, Manitoba June, 1999
403. Preclinical and Clinical Aspects of Anti-Angiogenic Strategies to Treat Cancer 35th Annual Meeting and Satellite Symposia, American Society of Clinical Oncology, Atlanta, Georgia May, 1999
404. Oncogenes, Resistance to Apoptosis & Tumor Angiogenesis: Links Established at the Preclinical Level Division of Hematology/Oncology, Case Western Reserve University, Cleveland May, 1999
405. Treating Cancer by Inhibiting Tumor Angiogenesis: Some Recent, and Promising, Advances Educational Session, Annual AACR meeting April, 1999
406. Signal Transduction Inhibitor Drugs as Anti-Angiogenic Agents 5th International Congress on Biological Response Modifiers, Inter-American Society for Chemotherapy April, 1999
407. Mechanisms of Tumor Cell Metastasis and Angiogenesis Columbia University, New York April, 1999
408. Linkages between Oncogenes, Resistance to Anoikis and Tumor Angiogenesis AACR 90th Annual Meeting, Philadelphia April, 1999
409. Molecular Determinants of Sensitivity to Anti-Tumor Agents Reversal of Cell Adhesion Dependent Multicellular Drug Resistance Keynote Lecture, AACR Special Conference March, 1999
410. Linking Different Fields: Oncogenes with Tumor Angiogenesis and Cell Adhesion with Resistance to Anti-Cancer Therapy Ohio State University, Columbus March, 1999
411. Impact of Oncogenes on Tumor Angiogenesis Institute for International Research Angiogenesis: Therapeutic Applications Conference, Bethesda February, 1999
412. Establishing Functional and Therapeutic Links between Oncogenes and Tumor Angiogenesis Distinguished Leaders in Medicine Lecture Series, Dalhousie University, Halifax February, 1999
413. Reversal of Cell Adhesion Dependent 'Multicellular' Drug Resistance Forbeck Foundation Focus Seminar on Tumor Invasion and Metastasis February, 1999
414. Esblishing Links between Different Fields: Oncogenes with Tumor Angiogenesis & Cell Adhesion with Drug Resistance University of Michigan Cancer Center, Ann Arbor January, 1999
415. Oncogenes and Angiogenesis First International Symposium on Anti-Angiogenic Agents, Irving (Dallas) January, 1999
416. Linking Oncogenes with Tumor Angiogenesis: Therapeutic and Biologic Implications Visiting Lecturer Series, City of Hope Comprehensive Cancer Center, Los Angeles December, 1998
417. Oncogenes as Generic Anti-Apoptotic and Pro-Angiogenic Factors Novartis Pharma, Osaka December, 1998
418. Oncogenes as Generic Anti-Apoptotic and Pro-Angiogenic Factors The 3rd Shizuoka Forum on Health and Longevity, Shizuoka, Japan December, 1998
419. Establishing Links Between Different Fields: Oncogenes with Tumor Angiogenesis and Cell Adhesion with Drug Resistance Karmanos Cancer Institute of Wayne State University, Detroit December, 1998
420. Impact of Cell Adhesion on Multicellular Drug Resistance in Solid Tumors, including Prostate Cancer AACR Special Conference - New Research Approaches in the Prevention and Cure of Prostate Cancer, Indian Wells December, 1998
421. Angiogenesis Inhibitors to Treat Cancer: Current Practise and Future Directions Eli Lilly Research Laboratories, Indianapolis, Indiana December, 1998
422. Establishing Links Between Different Fields: Oncogenes with Tumor Angiogenesis and Cell Adhesion with Drug Resistance Sankyo Co. Ltd., Tokyo, Japan November, 1998
423. Linking Oncogenes with Tumor Angiogenesis 29th International Princess Takamatsu Cancer Symposium, Tokyo, Japan November, 1998
424. Therapeutic Implications of Establishing a Link Between Oncogenes and Tumor Angiogenesis The Scripps Research Institute, La Jolla October, 1998
425. Therapeutic Implications of the Link Between Oncogenes and Tumor Angiogenesis Xth Edition of San Marino Conferences, Republic of San Marino, Italy October, 1998
426. Establishing a Basic and Therapeutic Link Between Oncogenes and Tumor Angiogenesis 4th Annual Cancer Symposium S Biologic Concepts in Cancer with Clinical Implications for the Year 2000 and Beyond, Penn State Geisinger's Milton S. Hershey Medical Center, Hershey October, 1998
427. Linkage Between Oncogenes and Tumor Angiogenesis VII International Congress of the Metastasis Research Society, San Diego October, 1998
428. Therapeutic Implications of Establishing a Link Between Oncogenes and Tumor Angiogenesis 10th Annual International Conference of the International Society of Differentiation, Houston October, 1998
429. Cell Adhesion as a Contributing Factor to Dormancy and Drug Resistance in Solid Tumors 2nd International Symposium on Minimal Residual Cancer, Berlin, Germany September, 1998
430. Establishing a Basic and Therapeutic Link between Oncogenes and Tumor Angiogenesis 67th Annual Meeting of The Royal College of Physicians and Surgeons of Canada, Canadian Society of Investigative Dermatology Lecture September, 1998
431. Therapeutic Implications of Cell Adhesion S Mediated Multicellular Drug Resistance in Solid Tumors CaP CURE's 5th Annual Scientific Retreat, Lake Tahoe, Nevada September, 1998
432. Linking Oncogenes and Signal Transduction with Tumor Angiogenesis The 13th Aspen Cancer Conference Workshop: Mechanisms of Toxicity and Carcinogenesis, Aspen July, 1998
433. Establishing Links between Oncogenes, Tumor Angiogenesis and Signal Transduction Therapy 4th Annual UPCI Biologic Therapy Retreat, University of Pittsburgh, Johnstown Campus July, 1998
434. Establishing a Basic and Therapeutic Link between Oncogenes and Tumor Angiogenesis American Association for Cancer Research Molecular Biology in Clinical Oncology" Workshop July, 1998
435. Impact of Cell Adhesion on Drug Resistance of Disseminated Tumors Harvard Medical School Department of Continuing Education and Massachusetts General Hospital, 13th Annual Offering of Critical Issues in Tumor Microcirculation, Angiogenesis and Metastasis, Biological Significance and Clinical Relevance Workshop June, 1998
436. Impact of Oncogenes and Signal Transduction Therapeutic Agents on Tumor Angiogenesis Universita degli Studi di Firenze, Dipartimento di Farmacologia, Florence, Italy June, 1998
437. Impact of Cell Adhesion on Drug Resistance of Disseminated Tumors 23rd Congress of the German Cancer Society, Berlin, Germany June, 1998
438. Impact of Oncogenes and Signal Transduction Therapeutic Agents on Tumor Angiogenesis Centre for Molecular Immunology, Havana, Cuba May, 1998
439. Impact of Oncogenes and Signal Transduction Therapeutic Agents on Tumor Angiogenesis 2nd Congress of Molecular Medicine, Berlin, Germany May, 1998
440. Establishing a Link between Oncogenes and Angiogenesis: Implications for Signal Transduction Therapy of Solid Tumors American Thoracic Society International Conference April, 1998
441. Therapeutic Implications of Establishing a Link Between Oncogenes and Angiogenesis The New York Academy of Sciences, New York April, 1998
442. New Horizons: Advances in Angiogenesis Research SHARE Educational Meeting, New York April, 1998
443. Therapeutic Implications of Establishing a Link Between the Genes that Cause Cancer and Tumor Angiogenesis Dept. of Medicine, Sunnybrook Health Science Centre, University of Toronto, Paterson Memorial Lecture April, 1998
444. Therapeutic Implications of Establishing a Link between Oncogenes and Tumor Angiogenesis Merck Research Laboratories, West Point March, 1998
445. Oncogenes and Tumor Angiogenesis American Association for Cancer Research, 89th Annual Meeting, New Orleans March, 1998
446. Tumor Angiogenesis: The Impact of Oncogenes" and "Impact of Cell Adhesion on the Induction and Reversal of Drug Resistance in Solid Tumors First Argentinean Conference on Cancer of the European School of Oncology, Buenos Aires March, 1998
447. Reversal of Intrinsic and Acquired Forms of Drug Resistance by Hyaluronidase Solid Tumors 5th Department of Internal Medicine with Oncology, Lainz Hospital, Symposium on Novel Aspects in Chemoresistance, Vienna March, 1998
448. The Link between Oncogenes and Tumor Angiogenesis The Wistar Institute, Philadelphia March, 1998
449. Impact of Oncogenes on Tumor Angiogenesis: Therapeutic Implications US/Japan NCI Conference on Tumor Angiogenesis, Maui, Hawaii February, 1998
450. Therapeutic Implications of Establishing a Link between Cell Adhesion and Drug Resistance in Cancer Breast Cancer Seminar Series at the Vanderbilt Cancer Center, Nashville February, 1998
451. Therapeutic Implications of Establishing a Link between Oncogenes and Tumor Angiogenesis American Association for Cancer Research Special Conference - Angiogenesis and Cancer January, 1998
452. Therapeutic Implications of Establishing a Link between Oncogenes and Tumor Angiogenesis Ontogen Corporation, Carlsbad January, 1998
453. Impact of Cell Adhesion on Induction and Reversal of Drug Resistance in Solid Tumors NASA Subgroup meeting of the American Society for Cell Biology, Washington December, 1997
454. Oncogenes and Tumor Angiogenesis Annual M.D. Anderson Cancer Symposium (Cancer Metastasis October, 1997
455. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer Glaxo Wellcome Pharmaceuticals, Raleigh Durham October, 1997
456. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer Centre du Recherche, Hotel Dien Hospital September, 1997
457. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer Canadian Association of Medical Oncologists Symposium on New Directions in Cancer Therapy, Royal College Meetings September, 1997
458. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer Aeterna Laboratoires, Quebec City September, 1997
459. Studies on Tumor Angiogenesis and Drug Resistance AnorMED Scientific Advisory Board meeting, Galiano Island, British Columbia, August, 1997
460. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer Gordon Research Conference on Tumor Angiogenesis and Microcirculation, Newport Rhode Island August, 1997
461. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer Gordon Research Conference on Cancer, Newport Rhode Island August, 1997
462. Impact of Cell Adhesion on Induction and Reversal of Multicellular Drug Resistance in Solid Tumors NCI/NIH Workshop on Physiologic Resistance of Solid Tumors, Washington July, 1997
463. What does an Oncogene do to Promote the Development and Spread of Solid Tumors?" American Association of Cancer Research course on Molecular Genetics of Cancer July, 1997
464. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer NCI/NIH Workshop on Tumor Angiogenesis, Bethesda Maryland June, 1997
465. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer Frederick/Cold Spring Harbor meeting on Tumor Suppressor Genes, Frederick Maryland June, 1997
466. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer OCTRF/McMaster University Meeting on Signal Transduction in Cancer, Hamilton May, 1997
467. What does an Oncogene do to Promote the Development and Spread of Solid Tumors? Educational Session of the American Association for Cancer Research April, 1997
468. Impact of Cell Adhesion on Induction and Reversal of Multicellular Drug Resistance in Solid Tumors NIH Pathology B Study Section Workshop, Keystone March, 1997
469. Impact of Cell Adhesion on Induction and Reversal of Multicellular Drug Resistance in Solid Tumors Oncology Research Program, Novartis Pharma, East Hanover March, 1997
470. Impact of Cell Adhesion on Induction and Reversal of Multicellular Drug Resistance in Solid Tumors Novartis Canada Roundtable Discussion on Multidrug Resistance in Cancer March, 1997
471. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer NexStar Pharmaceuticals, Boulder Colorado March, 1997
472. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer London Regional Cancer Centre, London March, 1997
473. Oncogene Regulation of Tumor Angiogenesis: Implications for Signal Transduction Therapy of Cancer Thomas Jefferson University Medical School February, 1997
474. AImpact of Oncogenes and Proto-oncogenes in Tumor Angiogenesis University of Viriginia, Charlottesville, Virginia December, 1996
475. Impact of Oncogenes and Proto-oncogenes in Tumor Angiogenesis. Wyeth Ayerst Pharmaceuticals, Pearl River, New York November, 1996
476. Impact of Oncogenes and Proto-oncogenes in Tumor Angiogenesis Institute for Immunology, University of Munich, Munich, Germany November, 1996
477. Impact of Oncogenes and Proto-oncogenes in Tumor Angiogenesis 3rd International Symposium, Impact of Cancer Biotechnology, Diagnostic & Prognostic Indicators October, 1996
478. Impact of Oncogenes and Proto-oncogenes in Tumor Angiogenesis Rhone-Poulenc Rohrer, Dept. of Oncology Research, Paris, France October, 1996
479. Induction and Therapeutic Reversal of Multicellular Drug Resistance in Solid Tumors Sandoz Research Inst., Dept. of Dermatology October, 1996
480. Role of Oncogenes and Proto-oncogenes in Tumor Angiogenesis International Society for Pediatric Oncology meeting, Vienna October, 1996
481. Oncogenes as Inducers of Tumor Angiogenesis: Biologic and Therapeutic Implications Robert Steel Foundation Symposium on Cancer Metastasis, Sloan-Kettering Memorial Institute September, 1996
482. Ras Oncogenes as Survival Factors in Transformed Intestinal Epithelial Cells Grown Three Dimensionally Symposium of the Crohns and Colitis Foundation, Tampa September, 1996
483. Oncogenes as Inducers of Tumor Angiogenesis: What are the Therapeutic Implications? Sapporo Cancer Foundation, University of Sapporo, Sapporo, Japan August, 1996
484. Multicellular Drug Resistance and its Therapeutic Reversal: Impact of Cell Adhesion and p27kip1 University of Sapporo, Sapporo August, 1996
485. Multicellular Drug Resistance in Solid Tumors: The Role of Cell Adhesion in its Induction and Reversal Plenary Lecture, International Congress on Human Cell Culture, Tokyo August, 1996
486. Role of Multicytokine Resistance in the malignant Switch of Primary human Cutaneous Melanomas" Sapporo Cancer Seminar, Sapporo July, 1996
487. Ras Oncogenes as Agents of Tumor Angiogenesis and Cell Survival in Solid Tumors Sankyo Inc July, 1996
488. Oncogenes as Inducers of Tumor Angiogenesis: Therapeutic Implications Takeda Chemical Industries, Osaka, Japan July, 1996
489. Oncogenes as Inducers of Tumor Angiogenesis: Therapeutic Implications Dept. of Obstetrics, Kyushu University, Fukuoka July, 1996
490. Multicellular Drug Resistance and its Reversal in Solid Tumor by Anti-Adhesive Agents Fukuoka Medical Association, Kyushu University, Fukuoka July, 1996
491. Multicellular Drug Resistance and its Reversal: Impact of Cell Adhesion and altered cell cycle Kinetics XIViem atelier annuel du groupe de recherche en transport membranaire, Université de Montreal May, 1996
492. Multicellular Drug Resistance in Solid Tumors and its Reversal by Anti-Adhesive Agents Institute for Immunology, University of Munich, Munich, Germany April, 1996
493. Ras Oncogenes as Regulators of Apoptosis and Angiogenesis in Solid Tumors Dr. Henry Shabata Honourary Lecture, Canadian Society for Surgical Oncology April, 1996
494. Ras Oncogenes as Regulators of Apoptosis and Angiogenesis in Solid Tumors Universite Louis Pasteur, NCRS, INSERM, Strasbourg April, 1996
495. Termination of the Dormant State in Pre-malignant Human Cutaneous Melanoma: An Experimental Model Behringer-Ingelhein Fonds Titisee Conference on Dormancy of Latent Infections and Cancer, Titisee March, 1996
496. Ras Oncogenes as Regulators of Apoptosis and Angiogenesis in Solid Tumors Sandoz Research Institute Symposium on In Vivo Models for Testing Anti-tumor Agents March, 1996
497. Multicellular Drug Resistance and its Reversal in Solid Tumors by Anti-Adhesive Agents. Rhone-Poulenc Rorer-CRVA/Biotechnologies, Paris February, 1996
498. Multicellular Drug Resistance and its Reversal in Solid Tumors by Anti-Adhesive Agents 6th International Congress on Anti-Cancer Treatments, Paris, February, 1996
499. Multicellular Drug Resistance and its Reversal in Solid Tumors by Anti-Adhesive Agents Curie Institute, INSERM, Paris February, 1996
500. Ras Oncogenes as Regulators of Apoptosis and Angiogenesis in Solid Tumors Rhone-Poulenc Rorer-CRVA/Biotechnologies February, 1996
501. Ras Oncogenes as Regulators of Apoptosis and Angiogenesis in Solid Tumors Cardinal Glennon Hospital, St. Louis, Missouri December, 1995
502. Ras Oncogenes as Regulators of Apoptosis and Angiogenesis in Solid Tumors" Howard Hughs Institute, Washington University, St. Louis, Missouri December, 1995
503. Ras Oncogenes and Cancer: Three Strikes and You're In ImClone Pharmaceuticals, New York November, 1995
504. Ras Oncogenes and Cancer: Three Strikes and You're In AACR Special Conference on Interface Between Clinical and Basic Research, Baltimore November, 1995
505. Ras Oncogenes Upregulate VEGF/VPF: Implications for Tumor Angiogenesis Behringer-Ingelheim Fonds Titisee Conference on Angiogenesis, Titisee, Germany November, 1995
506. Ras Oncogenes as Regulators of Angiogenesis and Apoptosis in Solid Tumors Wyeth-Ayerst Pharmaceuticals, Pearl River October, 1995
507. Ras Oncogenes as Regulators of Angiogenesis and Apoptosis in Solid Tumors Dept. of Tumor Biology, University of Freiburg, Freiburg Germany October, 1995
508. Impact of Multicellularity on the Growth and survival of Solid Tumors University of Quebec at Montreal, Dept. of Biochemistry September, 1995
509. Mutant Ras Oncogenes Upregulate VEGF/VPF: Implications for Induction and Inhibition of Angiogenesis Leukocyte Biology Conference, San Marco Island, Florida September, 1995
510. Multicelluar Drug Resistance and its Reversal in Breast Cancer International Society for Oncodevelopmental Biology and Medicine September, 1995
511. Mutant Ras Oncogenes Upregulate VEGF/VPF: Implications for Tumor Angiogenesis Gordon Research Conference on Angiogenesis and Microcirculation August, 1995
512. Multicellular Drug Resistance and its Reversal in Solid Tumors by Anti-Adhsive Agents" Int. Congress of Chemotherapy, Montreal July, 1995
513. Impact of multicellular architecture on the survival properties of solid tumors Symposium: NASA Bioreactor Symposia at the 1995 Congress on In Vitro Biology May, 1995
514. On the role of cell-cell adhesion in regulating drug resistance and cell survival in solid tumors McGill Cancer Centre, McGill University May, 1995
515. Multicellular resistance: an analysis of the enhanced survival properties of cells in solid tumors" German Tissue Culture Society International Conference on "Cell Interactions in Development, Malignancy and Differentiation" Heidelberg, Germany April, 1995
516. Multicellular resistance: an analysis of the enhanced survival properties of cells in solid tumors" Institut de Biologie, Institut National de la Santé et de la Recherche Médicale, Nantes April, 1995
517. The nature of the shift to the malignant phenotype during the progression of primary human cutaneous melanomas Annual Meeting of the American Association for Cancer Research March, 1995
518. Multicytokine resistance' and `cytokine switching' during melanoma progression University of Texas M.D. Anderson Cancer Center 38th Annual Clinical Conference "Advances in the Biology & Clinical Management of Melanoma February, 1995
519. Multicellular resistance: an analysis of the enhanced survival properties of cells in solid tumors Dartmouth-Hitchcock Medical Center, Department of Pharmacology and Toxicology, Hanover, February, 1995
520. A journey in experimental oncology: from metastasis to drug resistance C and back" R.E. "Bob" Smith Lecturer University of Texas M.D Anderson Cancer Center, Houston January, 1995
521. Inhibition of angiogenesis as a strategy to circumvent the problem of acquired drug resistance in cancer Sandoz Research Institute, Oncology Program January, 1995
522. Acquired Multicellular Drug Resistance in Solid Tumors Annual Meeting of the Norwegian Oncology Society, Oslo December, 1994
523. Acquired Multicellular Drug Resistance in Solid Tumors Department of Tumor Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo November, 1994
524. Multicytokine Resistance in Human Malignant Melanoma Fukuoka Medical Association, Fukuoka, Japan November, 1994
525. Acquired Multicellular Drug Resistance in Solid Tumors 4th Kyushu Gynecologic Oncology Conference, Kyushu University, Fukuoka November, 1994
526. Multicytokine Resistance in Human Malignant Melanoma." Tokyo Immunology Club, Juntendo University, Tokyo November, 1994
527. Acquired Multicellular Drug Resistance in Solid Tumors National Cancer Research Centre November, 1994
528. Acquired Multicellular Drug Resistance in Solid Tumors Sankyo Co. Ltd., Tokyo, Japan November, 1994
529. Acquired Multicellular Drug Resistance in Solid Tumors Society of Urological Biology and Research Meeting, Stanford University, Palo Alto October, 1994
530. Impact of Multicellular Contact on Drug Induced Apoptosis Induced in Solid Tumors W. Alton Jones Symposium on Programmed Cell Death, Lake Placid September, 1994
531. Acquired Multicellular Drug Resistance in Solid Tumors Genentech, San Francisco August, 1994
532. Multicytokine Resistance and the Role of IL-6 in Human Malignant Melanoma Amgen Workshop on Stem Cell Factor and its Role in Melanocyte Biology and Pigmentation, Thousand Oaks July, 1994
533. Acquired `multicellular' drug resistance in mouse and human cancers 59th Cold Spring Harbor Symposium on Molecular Genetics of Human Cancer June, 1994
534. Multicytokine resistance in malignant melanoma Dept. of Cell Biology, Vanderbilt University May, 1994
535. Acquired `multicellular' drug resistance in mouse and human cancers," Burroughs-Wellcome, Raleigh-Durham May, 1994
536. Acquired multicellular resistance to chemotherapeutic drugs: A new paradigm Dept. of Cell Biology, Vanderbilt University May, 1994
537. Acquired multicellular resistance to chemotherapeutic drugs: A new paradigm." Radiation Research Society and North American Hyperthermia Society, "Tumor microenvironments and regulation of gene expression May, 1994
538. Acquired multicellular resistance to alkylating agents: A new paradigm for drug resistance in solid tumors Sandoz Research Institute, East Hannover April, 1994
539. Multicytokine resistance in malignant melanoma." British Association for Cancer Research/ACP, Birmingha March, 1994
540. Cytokine regulation of melanoma cell growth and multicytokine resistance as a factor in malignant progression and metastasis AACR Special Conference in Cancer Research, "Molecular genetics of tumor progression and metastasis." Big Sky, Montana February, 1994
541. Acquired multicellular resistance to alkylating agents: A new paradigm for drug resistance in solid tumors NYU Medical Center February, 1994
542. Molecular pathobiology of metastasis: Human malignant melanoma as a paradigm New York University Medical Centre, New York February, 1994
543. New paradigm for acquired drug resistance in solid tumors City Wide Oncology Rounds, Women's College Hospital, Toronto January, 1994
544. Acquired multicelular drug resistance in cancer: basic science and possible clinical significance Science Park, M.D. Anderson Cancer Center, Austin, Texas November, 1993
545. Acquired multicellular drug resistance in cancer: basic science and possible clinical significance Dept. of Pathology, Beth Israel Hospital, Harvard University, Boston, MA November, 1993
546. Acquired multicytokine resistance in human malignant melanoma progression and its possible impact on metastasis Ciano Memorial Lectureship, Dept. of Pathology, Beth Israel Hospital, Harvard University November, 1993
547. Loss of multiple negative growth controls during human tumor progression M.D.Anderson Cancer Center's Clinical Conference and Annual Special Pathology Program, "Advances in the Biology and Therapy of Colorectal Cancer" Houston November, 1993
548. Acquired multicellular drug resistance in cancer: basic science and possible clinical significance Dept. of Pathology, University of Minneapolis November, 1993
549. Acquired multicellular drug resistance in cancer: experimental analysis and clinical implications Visiting Distinguished Professor) University of Beijing, Beijing October, 1993
550. Acquired multicellular drug resistance in cancer: experimental analysis and clinical implications Grace Drug Cancer Center, Rosewell Park Memorial Institute September, 1993
551. Development of multicytokine resistance during tumor progression in human melanoma Keynote Lecture, Canadian Association of Pathologists, Kingston September, 1993
552. Acquired multicellular drug resistance in cancer: experimental analysis and clinical implications Sandoz Pharmaceuticals, East Hanover August, 1993
553. Multicytokine resistance in advanced stage human malignant melanoma: characteristics and significance McMaster University, Hamilton June, 1993
554. Acquired multicellular drug resistance in cancer Hamilton Regional Cancer Centre, Hamilton June, 1993
555. Plenary session entitled "Tumor Invasion, Angiogenesis, and Metastasis" at Annual Meeting of the American Association for Cancer Research Transition stages in multicytokine responsiveness during tumor progression: human malignant melanoma as a paradigm May, 1993
556. Cellular and molecular biology of metastasis Meet the expert sunrise session at Annual Meeting of the American Association for Cancer Research May, 1993
557. Acquired multicellular resistance to alkylating agents as a new paradigm for acquired drug resistance in cancer Dana Farber Cancer Center, Harvard University April, 1993
558. Acquired multicellular resistance to alkylating agents as a new paradigm for acquired drug resistance in cancer Dept. of Radiation Oncology, Harvard Medical School, Massachusetts General Hospital April, 1993
559. Multicytokine resistance' of advanced stage human melanoma cells Third annual symposium on Growth Factors and Cytokines in Melanoma Cell Growth at Venice April, 1993
560. Acquired multicellular resistance to alkylating agents as a new paradigm for acquired drug resistance in cancer" and "Evolution of multicytokine resistance and multigrowth factor independence during disease progression in human melanoma Keystone Symposia on Molecular and Cellular Biology March, 1993
561. Evolution of multicyokine resistance and multigrowth factor independence during disease progression in human melanoma International symposium on Approaches to Cancer Prevention and Early Diagnosis at Montreux March, 1993
562. Development of multicytokine resistance and multi-growth factor independence during human malignant melanoma progression Sandoz Research Institute, Oncology, Sandoz Pharmaceuticals Corporation, East Hanover February, 1993
563. Multicytokine resistance of advanced stage human melanoma cells: implications for tumor progression Stratton VA Medical Center Research Servies, Seminar Series, Department of Veterans Affairs November, 1992
564. Multicytokine resistance of advanced stage human melanoma cells: implications for tumor progression Cancer Center Grand Rounds, University of Michigan, Ann Arbor, Michigan November, 1992
565. A new understanding of the role of matrix metalloproteinases in tumor biology The Upjohn Co., Brook Lodge, Kalamazoo, Michigan September, 1992
566. Advanced-stage cancers can manifest a multi-growth inhibitor resistant phenotype: implications for metastasis Fourth International Congress of the Metastasis Research Society, Science and Medicine in Cancer Metastasis, Paris, France September, 1992
567. Advanced-stage metastatic cancer cells may express a multi-growth inhibitor resistant phenotype International Union of Biochemistry and Molecular Biology of Disease, Nagoya June, 1992
568. Ares Serono International Symposium on Heterogeneity of Cancer Cells. Interleukin-6 is a paracrine growth inhibitor of early but not advanced stage human melanoma cells: implications for metastasis June, 1992
569. Advanced-stage metastatic cancer cells may express a multi-growth inhibitor resistant phenotype Ajinomoto Co. Inc., Nagoya, Japan June, 1992
570. Interleukin-6: from paracrine growth inhibitor to autocrine stimulator during human melanoma progression University of Tokyo, Tokyo, Japan June, 1992
571. Interleukin-6 is a growth inhibitor of early but not advanced stage human melanoma cells: implications for cancer metastasis Montreal Cancer Institute, Montreal, Quebec April, 1992
572. Interleukin-6: from paracrine growth inhibitor to autocrine stimulator during human melanoma progression National Cancer Research Centre, Tokyo, Japan April, 1992
573. Molecular genetic alterations underlying human colorectal carcinoma: pathobiologic implications and clinical application Symposium, Recent Advances in Biology, Treatment, and Management of Colorectal Cancer, Ottawa Regional Cancer Centre March, 1992
574. Inhibitory growth factors involved in `clonal dominance' of metastatically competent tumor cells in human malignant melanoma Fourth Lorne Cancer Conference, Erskine House, Lorne February, 1992
575. Advanced stage human malignant melanomas express a multi-growth inhibitor resistance phenotype: implication for metastasis McGill University Centre for the study of host resistance, Montreal January, 1992
576. Growth factors in cancer progression and metastasis Grand Rounds, Princess Margaret Hospital December, 1991
577. Pleiotropic growth inhibitor resistance in advanced stage cancer: Analysis and clinical implications Sudbury Regional Cancer Centre December, 1991
578. Pleiotropic resistance to multiple growth inhibitors: A feature of advanced stage metastatic cancer Distinguished Visiting Scientist Lecture Series, Michigan Cancer Foundation, Detroit December, 1991
579. Contribution of paracrine growth gactors in clonal dominance of primary melanomas by metastatically-competent tumor cells Philadelphia Cancer Research Meeting November, 1991
580. Multi-growth inhibitor resistance: A feature of advanced-stage human melanoma cells Annual Morris Fanny May Symposium on Cancer: Molecular Biology of Metastasis, Notre Dame University November, 1991
581. Local and systemic paracrine inhibitory growth factors in human melanoma metastasis Annual Clinical Conference, M.D. Anderson Cancer Centre, on Advances in the Biology and Clinical Management of Melanoma November, 1991
582. Inhibition of tumor angiogenesis as a paradigm to circumvent the problem of acquired resistance to antineoplastic agents N.I.H. (Experimental Therapeutics) Workshop on New Molecular Targets in Cancer Therapy, Bethesda November, 1991
583. Interleukin-6: A paracrine growth inhibitor of early but not advanced-stage human melanomas Ciba-Geigy Ltd., Basel, Switzerland November, 1991
584. Inhibition of tumor angiogenesis O.C.T.R.F. Lake Couchiching Meeting on Basic and Clinical Advances in Cancer October, 1991
585. Interleukin-6: A paracrine growth inhibitor of early but not advanced-stage human melanomas Sandoz Pharmaceuticals, Basel, Switzerland October, 1991
586. Paracrine growth factors in relationship to the `growth dominant' metastatic cancer cell Mildred Scheel Stiftung Symposium on Metastasis: Basic Research and Clinical Applications October, 1991
587. Chairman's introduction and overview 1991 Gordon Research Conference on Cancer, August, 1991
588. The growth-dominant metastatic phenotype: biological analysis and clinical implications". Department of Biological Sciences, SUNY, Stonybrook, N.Y. May, 1991
589. Molecular genetics of human cancer Surgical Grand Rounds, Sunnybrook Health Science Centre May, 1991
590. The growth-dominant metastatic cell phenotype Glaxo Pharmaceuticals April, 1991
591. The growth-dominant metastatic cell phenotype: human melanoma as a paradigm University of North Carolina Lineburger Cancer Centre, Chapel Hill, N.C April, 1991
592. Clonal dominance of primary tumors by metastatically-competent tumor cells: genetic analysis and role of growth factors N.I.H. Pathology B Study Section, Workshop on Genetic Instability in Cancer February, 1991
593. Biological aspects of human melanoma metastasis Plenary lecture of the 3rd meeting of the Pan American Society for Pigment Cell Research January, 1991
594. Clinically Relevant Patterns of Metastasis of Human Malignant Melanoma in Nude Mice: Role of Host Tissue Environment British Association for Cancer Research Meeting November, 1990
595. Contribution of TGFβ in Clonal Dominance and Cancer Metastasis Third International Congress in Metastasis Research, Bethesda September, 1990
596. Recent Developments in Human Tumor Xenografting and their Application to Genetics of Cancer Development National Disease Research Interchange, Washington September, 1990
597. Genetics of Colorectal Carcinoma in Man Canadian College of Physicians and Surgeons Meeting September, 1990
598. Role of Cell-cell Interactions in Clonal Dominance of Metastatically Competent Tumor Cell Variants in Primary Tumors Karger Symposium on Cell-Cell Interactions, Basel, Switzerland September, 1990
599. The Growth Dominant Metastatic Cancer Cell: Cellular and Molecular Aspects Gordon Conference on Cancer, Newport, R.I August, 1990
600. On the Nature of the Growth Advantage of Metastatic Cancer Cells FASEB Summer Research on Molecular Aspects of Metastasis Conference, Saxton River July, 1990
601. Cytokine Selection of Metastatic Tumor Subpopulations Major Symposium, American Association for Cancer Research Meeting, Washington May, 1990
602. The Growth Dominant Metastatic Phenotype: Biological Analysis and Clinical Implications Dept. of Anatomy, University of Western Ontario, London March, 1990
603. The Growth Dominant Metastatic Phenotype: Biological Analysis and Clinical Implications Institute for Cancer Research, London (Sutton) England, U.K. January, 1990
604. The Metastatic Cell as a Highly Efficient Cellular Scavenger Dept. of Cell Biology, M.D. Anderson Hospital and Tumor Institute, Houston December, 1989
605. The Metastatic Cell as a Highly Efficient Cellular Scavenger Dalhousie University, Halifax November, 1989
606. Clonal Dominance of Primary Tumors by Metastatically Competent Cells: Genetic Analysis and Implications with Respect to Drug Resistance Scripps Clinic and Research Foundation, Dept. of Tumor Biology, San Diego September, 1989
607. Clonal Dominnace of Primary Tumors by Metastatically Competent Cells: Genetic Analysis and Implications with Respect to Drug Resistance Roswell Park Memorial Institute, Grace Drug Cancer Center, Buffalo September, 1989
608. Lineage Analysis of Tumor Progression Gordon Conference on Cancer, R.I., U.S.A., August, 1989
609. Clonal Dominance of Primary Tumors by Metastatically Competent Cells: Genetic Analysis, Mechanisms & Biological Implications Wistar Institute of Biology and Medicine, Philadelphia June, 1989
610. Clonal Dominance of Primary Tumors by Metastatically Competent Cells: Genetic Analysis, Mechanisms & Biological Implications University of Wisconsin, Dept. of Human Oncology, Madison April, 1989
611. Genetic Analysis of Tumor Progression University of California at San Diego, UCSD Cancer Centre April, 1989
612. Clonal Dominance of Primary Tumors by Metastatically Competent Cells: Genetic Analysis, Mechanisms & Biological Implications University of Southern California, Comprehensive Cancer Centre, Los Angeles, California March, 1989
613. Clonal Dominance of Metastatic Tumor Cells During Tumor Progression International Conference of Critical Determinants in Metastasis". Houston, Texas, March, 1989
614. Clonal Dominance of Primary Tumors by Metastatically Competent Cells: Genetic Analysis, Mechanisms & Biological Implications Ontario Cancer Foundation Clinic, Kingston, Ontario February, 1989
615. Molecular Genetic Analysis of Tumor Progression UCLA Symposium on Molecular and Cellular Biology: Carcinogenesis and Tumor Progression, Keystone January, 1989
616. Clonal dominance of primary tumors by metastatic subpopulations: molecular genetic analysis and biological implications Dept. of Biochemistry, University of Illinois, Chicago, Illinois November, 1988
617. Genetic and pathobiological analysis of progressive tumor growth and metastatic disease Dept. of Anatomy, University of Toronto November, 1988
618. Clonal dominance of metastatically competent cell subpopulations in primary tumors: genetic analysis and biological implications International Metastasis of the Metastasis Research Society, Heidelberg September, 1988
619. New Animal Model to Study Human Malignant Melanoma R. E. Smith Workshop on Malignant Melanoma, Galveston September, 1988
620. New Approach to Study the Biology and Treatment of Human Malignant Melanoma Esai Research Laboratories, Tsukuba, Japan July, 1988
621. New Approach to Study the Biology and Treatment of Human Malignant Melanoma Ajinimoto Research Laboratories, Tokyo, Japan July, 1988
622. Clonal dominance of metastatically competent cells in primary tumors Sapporo Cancer Seminar (Metastasis) Sapporo, Japan July, 1988
623. The cellular and molecular biology of tumor progression and metastasis National Cancer Institute of Canada, Oncology Course for Graduate Students, McMaster University June, 1988
624. Somatic cell and molecular genetic approaches to study tumor progression and metastasis German Cancer Research Centre, Heidelberg, Germany April, 1988
625. Use of Gene transfer to study known progression and metastasis Ludwig Cancer Research Institute, Lausanne, Switzerland April, 1988
626. Clonal changes in tumors during growth and progression evaluated by southern gel analysis of random integrations of foreign DNA CIBA Foundation Symposium (#141) on Metastasis, London April, 1988
627. Application of gene transfer technology to study tumor evolution, and metastasis". Dept. of Pathology, University of Gainesville, Gainesville, Florida March, 1988
628. Cell Biology of Human Melanoma Metastasis Dept. of Cell Biology, M. D. Anderson, Hospital and Tumor Institute, Houston January, 1988
629. Gene transfer techniques reveal new aspects of the lineage relationships between primary tumors and metastases Frederick Cancer Research Facility, Frederick, Maryland January, 1988
630. Clonal Evolution of Tumor Progression - a New Method of Experimental Analysis". Grands Rounds lecture in Oncology. Hospital for Sick Children, Toronto January, 1988
631. Molecular Genetic Approach to Study Clonal Evolution of Tumor Growth and Lineage Relationships of Primary Tumors to Metastases N.C.I.(USA) Workshop on New Strategies to Study Cancer Metastasis, Alexandria November, 1987
632. The metastatic process: Analysis using gene transfection procedures Second Batsheva Symposium on Metastasis Elat, Israel September, 1987
633. Session Chairman's Introduction to Session on Tumor Heterogeneity Gordon Conference on Cancer, New London, New Hampshire August, 1987
634. Application of gene transfer procedures to study tumor growth and metastasis in vivo International Society of Differentiation meeting on Differentiation of Normal and Neoplastic Cells, Boulder Colorado August, 1987
635. Analysis of Tumor Progression and Metastasis by Gene Transfer Methodology Department of Experimental Oncology, Ottawa Regional Cancer Center, Ottawa June, 1987
636. Biological Analysis of the Metastatic Phenotype Canadian Society of Clinical Chemistry, Ottawa June, 1987
637. Gene Transfection in the Study of Tumor Progression and Metastasis International Congress on Cancer Metastasis: Biological and Biochemical Mechanisms and Clinical May, 1987
638. Analysis of Tumor Progression and Metastasis by Gene Transfer Technology Molecular Genetics and Carcinoma Laboratory, Cross Cancer Institute, Edmonton April, 1987
639. Mechanisms of Tumor Progression Keynote Scientific Address delivered to M.D. Anderson Symposium on The Realities of Cancer in Minority Communities April, 1987
640. Analysis of Tumor Progression and Metastasis by Gene Transfer Technology Oncology Research Group, University of Calgary, Calgary, Alberta April, 1987
641. New Approaches to Overcoming the Problem of Resistance to Anti-cancer Therapeutic Agents Molecular Genetics and Carcinoma Laboratory, Cross Cancer Institute, Edmonton April, 1987
642. Probing Genetic and Epigenetic Aspects of Tumor Progression Using Transplantable Mouse Tumors or Human Tumor Xenografts UCLA Symposium on Molecular and Cellular Biology: Tumor Progression and Metastasis, Keystone, Colorado April, 1987
643. Approaches to Study the Genetic and Biochemical Nature of the Cancer Cell Metastatic Phenotype Dept. of Anatomy, University of Western Ontario, London, Ontario March, 1987
644. Impact of Tumor Cell Heterogeneity on Immunological Aspects of Tumor Growth: The "Tum-" Phenomenon OCTRF Clinic, University of Western Ontario, London, Ontario March, 1987
645. Genetic Analysis of Tumor Growth, Progression and Metastasis McMaster University Graduate Students in Medical Research Lecture February, 1987
646. New concepts relevant to tumor progression Annual Forbeck (Neuroblastoma) Foundation Think Tank, Hilton Head November, 1986
647. Application of Molecular Genetic Techniques to the Study of Tumor Progression and Metastasis Smith Kline and Beckman Corporation, Philadelphia, November, 1986
648. Nature and implications of the "tum-" phenomenon R. E. Bob Smith Workshop on Antigenic Modification of Tumor Cells, Galveston September, 1986
649. The fluidity of the mammalian genome: consequences for tumor progression and tumor cell heterogeneity American Society of Clinical Pathologists Meeting, Orlando, Florida September, 1986
650. Gordon Research Conference on Cancer, Session Chairman's Introduction. New London, New Hampshir August, 1986
651. High frequency drug-induced alterations in the malignant and antigenic phenotype of cultured neoplastic cells Tissue Culture Association Meeting June, 1986
652. Analysis and implications of heritable alteration in malignancy induced by exposure of neoplastic cells to chemotherapeutic agents or DNA-mediated transfection procedures Roswell Park Memorial Res. Inst. Research Day, Buffalo June, 1986
653. Epigenetic aspects of metastasis and tumor progression: implications for cancer therapy Mt. Sinai Hospital Research Institute Opening Symposium, Toronto, Ontario June, 1986
654. Tumor Cell Heterogeneity and Tumor Progression 5th NCIC Course on Oncology, McMaster University, Hamilton June, 1986
655. Tumor Progression BIOS Research Meeting, Toronto May, 1986
656. DNA methylation and gene expression in tumor progression Peralta Cancer Conference (10th Anniversary of Peralta Centre), Oakland May, 1986
657. Genetic and epigenetic aspects of tumor progression and the metastatic phenotype Meeting on Biological and Therapeutic Aspects of Cancer Metastasis, Vitoria April, 1986
658. Darwinian evolutionary processes as they apply to the progression of cancer Dept. of Biology, York University, Toronto February, 1986
659. Implications of therapy-induced genetic/epigenetic modulations of tumor progression and tumor cell heterogeneity Med Tech' 86 Cancer Symposium Celebrating Opening of the F.Lee Moffit Cancer Centre, Tampa January, 1986
660. Heritable high frequency alterations induced in the malignant phenotype of tumor cells exposed to alkylating or DNA hypomethylating agents Arizona Cancer Centre, Tuscon, Arizona December, 1985
661. Genetic and epigenetic aspects of tumor progression International Workshop on Tumor Heterogeneity, Tumor Progression, Drug Resistance and Metastasis at the First Int. Congress of Neo-Adjuvant Chemotherapy November, 1985
662. Heritable alterations of variable stability in the malignant properties of tumor cells exposed to chemotherapeutic drugs or differentiating agents Brook Lodge/Upjohn Symposium on Cancer Metastasis: Experimental and Clinical Strategies, Kalamazoo, Michigan September, 1985
663. Epigenetic considerations of tumor Progression: methylation and malignancy Gordon Conference on Cancer, Colby-Sayer College, New London, New Hampshire, August, 1985
664. Genetic and epigenetic aspects of the metastatic phenotype studied using transplantable mouse tumors and human tumor xenografts Institute of Tuberculosis and Cancer, Tohoku University June, 1985
665. Genetic and epigenetic aspects of the metastatic phenotype studied using transplantable mouse tumors and human tumor xenografts Symposium on Cancer Metastasis, Sapporo June, 1985
666. Genetic and epigenetic aspects of the metastatic phenotype studied using transplantable mouse tumors and human tumor xenografts National Cancer Institute, Tokyo, Japan June, 1985
667. Genetic and epigenetic mechanisms for the development of metastatic heterogeneity in neoplasms Major Plenary Lecture of the American Association for Cancer Research, Houston May, 1985
668. Genetic and epigenetic aspects of the metastatic phenotype International Meeting on Differentiation of Normal and Neoplastic Cells. Heidelberg May, 1985
669. Genetic epigenetic and immunological aspects of the metastatic phenotype Department of Microbiology & Immunology, Wayne State University April, 1985
670. Genetic and epigenetic considerations of the metastatic phenotype Department of Radiobiology and Oncology, University of Rochester, Rochester March, 1985
671. An Approach to the study of the contribution of the plasma membrane to metastasis Canadian Cell Biology Meeting, Banff, Alberta March, 1985
672. Epigenetic aspects of metastasis Fogarty International Symposium on Biochemistry and Molecular Genetics of Cancer Metastasis March, 1985
673. Genetic and epigenetic considerations of the metastatic phenotype Ontario Cancer Institute, Toronto January, 1985
674. Prototypes of cancer therapy which may circumvent the problem of tumor cell heterogeneity: Anti-Angrogenesis Grand Rounds, Ontario Cancer Institute, Princess Margaret Hospital, December, 1984
675. Problems and pitfalls in the use of animal models to study aspects of cancer, (especially tumor immunology)". Terry Fox Graduate Course in Tumor Biology, Ontario Cancer Institute December, 1984
676. Impact of tumor cell heterogeneity on therapeutic failures in the treatment of cancer Canadian Cancer Society Meeting, Toronto, Ontario November, 1984
677. Genetic and epigenetic aspects of tumor progression and metastasis". Montreal Cancer Institute, Montreal, Quebec November, 1984
678. DNA methylation and malignancy Meeting on: DNA Methylation and Cancer, Philadelphia October, 1984
679. Recent progress in cancer research Mount Sinai Hospital Womens Auxiliary, Toronto October, 1984
680. Alterations of tumor cell immunogenicity induced by mutagens". International Meeting on Biological Response Modifiers and Cancer, Hakone, Japan September, 1984
681. Prototypes of cancer therapies which may circumvent the problem of tumor cell heterogeneity and resistance to therapy Meeting on Cancer Therapy: Where do we go from here? Jackson Hole, Wyoming September, 1984
682. Genetic and epigenetic aspects of the metastatic phenotype Chiba Cancer Centre, Chiba, Japan September, 1984
683. Epigenetic mechanisms in the development of tumor cell heterogeneity Terry Fox Meeting on Cancer Research, (Cancer and Epigenetics), Vancouver, British Columbia August, 1984
684. Spontaneous cell fusion in malignancy: relevance to neoplasia Cancer Research Laboratory, Experimental Pathology Group, Los Alamos National Laboratory June, 1984
685. Genetic and epigenetic aspects of tumor progression and tumor cell heterogeneity: some biological and biochemical considerations Canadian Association of Pathologists, Halifax, Nova Scotia, June, 1984
686. High frequency changes induced in the malignant properties of tumor cell populations by low doses of 5-azacytidine, a poorly mutagenic DNA hypomethylating agent Brookhaven Symposium on Assessment of Risk from Low-Level Exposure to Radiation and Chemicals: A Critical Overview. Upton May, 1984
687. Tumor heterogeneity and its relevance to metastasis Department of Pathology, University of Gainesville February, 1984
688. Effects of 5-azacytidine, a DNA hypomethylating agent, on malignant properties of tumor cells: implications for tumor progression Meeting on DNA Methylation & Cancer, Smith, Kline & Beckman Co., Philadelphia, Pennsylvania November, 1983
689. Tumor cell-host cell fusion in vivo: possible contribution to tumor progression and metastasis Laboratory of Pulmonary Function and Toxicology, NIH Environmental Health Sciences Research, Triangle Park October, 1983
690. Aspects of tumor progression Molecular and cellular biology of neoplasia. Honey Harbor October, 1983
691. DNA hypomethylation as a possible mechanism of tumor heterogeneity and tumor cell phenotypic instability 1st Annual UICC Workshop on Basic and Clinical Aspects of Cancer: September, 1983
692. DNA hypomethylation as a possible mechanism of tumor heterogeneity and tumor cell phenotypic instability Gordon Conference on Cancer, New Hampshire August, 1983
693. Spontaneous fusion in vivo between tumor cells and normal host cells as a possible means of generating tumor progression and metastatic variants Bat Sheva Rothschild Conference on Metastasis, Tiberius May, 1983
694. Origin and implications of tumor heterogeneity New York University (NYU) Bellevue Hospital March, 1983
695. Spontaneous fusion in vivo between tumor cells and normal host cells as a possible means of generating tumor progression and metastatic variants 1983 M.D. Anderson Symposium on Fundamental Cancer Research: Invasion & Metastasis, Houston March, 1983
696. The biology of cancer metastasis and tumor heterogeneity studied with lectin resistant membrane mutant tumor sublines Department of Microbiology and Immunology, McGill University, Montreal November, 1982
697. Somatic cell hybridization in relation to metastasis and tumor progression Ontario Cancer Institute, Toronto, Ontario October, 1982
698. Somatic cell hybridization in relation to metastasis and tumor progression NCI Frederick Cancer Research Facility, Frederick October, 1982
699. Impact of tumor heterogeneity on tumor marker studies Meeting on Colonic Carcinoma, sponsored by U.S. NCI), Southwest Harbor, Maine September, 1982
700. Tumor immunology & experimental oncology Third NCI(C) course in cancer research for graduate students June, 1982
701. Tumor progression in cancer metastasis: studies using membrane mutant tumor variants Chester Beatty Research Institute, London, England May, 1982
702. Tumor progression in cancer metastasis: studies using membrane mutant tumor variants Department of Pathology, McMaster University, Hamilton, Ontario May, 1982
703. Somatic cell hybridization as a possible means of generating tumor cell diversity and more malignant variants Departments of Bacteriology, Oncology & Cancer Research Laboratories, University of Western Ontario, London April, 1982
704. Somatic cell hybridization as a possible means of generating tumor cell diversity and more malignant variants Department of Microbiology & Immunology, University of California at Irvine, Irvine, California March, 1982
705. Tumor progression in cancer metastasis: studies using membrane mutant tumor variants". Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia February, 1982
706. Tumor progression in cancer metastasis: studies using membrane mutant tumor variants Department of Pathology & Therapeutics, University of Calgary, Calgary, Alberta February, 1982
707. Tumor progression in cancer metastasis: studies using membrane mutant tumor variants Institute of Immunology, University of Toronto, Toronto, Ontario February, 1982
708. Implications of tumor heterogeneity Department of Pathology, University of Toronto, Toronto, Ontario February, 1982



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
Models of postsurgical early and late stage metastasis for improving preclinical adjuvant and metastatic therapy investigations Tumor Invasion and Metastasis January, 2013
Improving the prospects of preclinical models to predict investigational drug efficacy in the clinic and clinical trials 3rd WIN Symposium July, 2011
Recent issues emerging from the use of antiangiogenic drugs in the clinic Idibell Cancer Conference on Metastasis and Angiogenesis May, 2011
Abnormalities of the Tumor Microvascular Network Angiogenesis and Lymphangiogenesis in Cancer (A2) January, 2009

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.